The role of antigen receptor signaling in activation and development of invariant Natural Killer T cells by Holzapfel, Keli Lee
  
 
 
The Role of Antigen Receptor Signaling in Activation and Development of invariant 
Natural Killer T Cells 
 
 
 
 
A Dissertation 
SUBMITTED TO THE FACULTY OF  
UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Keli Lee Holzapfel 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF  
DOCTOR OF PHILOSOPHY 
 
 
 
Advisor: Kristin A. Hogquist, PhD  
 
 
 
 
May 2014 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Keli Lee Holzapfel 2014 
 
  i 
Acknowledgements 
 First and foremost, I want to thank my advisor, Kris Hogquist.  Not only is she an 
amazing scientist, but she is a great mentor and pushed me to become a better scientist. I 
also want to thank Steve Jameson for all his input and humor during lab meetings.  
Additionally, both past and present members of the Jamequist lab were essential for the 
completion of this thesis.  More specifically, Amy Moran introduced to me the world of 
immunology and was the leader of Team Nur77.  Jane Ding kept the lab running, and was 
always ready to host a party.  Gretta Stritesky, Cara Skon, Janelle Olson, Ross Fulton and 
Sara Hamilton made lab both a fun and intellectually stimulating environment.  You-
Jeong Lee was my iNKT cell guru and helped me with techniques and experiments.  
June-Yong Lee and Yan Xing always provided helpful feedback.  Sam Dunmire was my 
fellow classmate, with whom I shared all the milestones of grad school with, whether it 
was surviving prelims or doing practice talks for student seminar.  I also want to thank 
everyone in the Center for Immunology for their helpful feedback during Supergroup, 
and willingness to help with new techniques and discuss experiments. 
 All my grad school classmates were instrumental in helping me to keep my sanity.  
Dana Strandjord, Joe Belanto, Jami Erickson, Luke Manlove, and Alli O’Rourke were 
always around to make bad experiment days better, and to go on crazy adventures with 
me outside of lab.  My college friends, Jennica Corry, Laura Slater, Christina Koehn, 
Megan Knox, Talia Tupling, Morgan Clary, Sara Fergusson, Stacey McFerran, and Katie 
  ii 
Garrison kept me grounded during this whole experience, and reminded me that there is 
life outside the lab.  My “Minnesota family,” Kris, Craig, Paul, Shannon, Jenny, Jeff, 
Jonathan, Nora, Aidan, Laurie, and Kyle, were a tremendous support system, and words 
cannot express my gratitude for all that they have done for me over the last six years. 
 Most of all, I want to thank my family.  My parents, George and Patsy, my sisters, 
Kari and Marie, and their husbands, Troy and Chris, were always supportive and helped 
me make it through the tough semesters of trying to balance lab and law school.  I also 
want to thank my niece, Heidi, and nephew, Hayes, for reminding how wonderful and 
amazing it is to learning new things, and not to take the little things for granted. 
  iii 
Dedication 
 
This thesis is dedicated to my parents, George and Patsy Holzapfel.  Without their love 
and support, this thesis would not have been possible. 
  iv 
Abstract 
CD1d-reactive invariant Natural Killer T cells (iNKT) are a T cell subset that 
have characteristics of both innate immune cells and adaptive immune cells.  As a result, 
they are considered a bridge between the innate and the adaptive immune response.  
iNKT cells can rapidly secrete a variety of cytokines after activation, and therefore have 
an important immunomodulatory role during the immune response in many different 
diseases, such as cancer, asthma, autoimmune disease, and infection.  During infections, 
there are three models of iNKT cell activation: activation requiring microbial antigen, 
cytokine driven activation, and activation requiring self-antigen.  However, how iNKT 
cells become activated during some infections remains controversial, as activation 
requiring self-antigen has only been indirectly shown.  Therefore, I addressed this 
controversy using an antigen receptor signal strength reporter mouse, in which Nur77
gfp
 
reports stimulation of the T cell receptor (TCR).  Although the sensitivity of this reporter 
mouse was initially observed in conventional T cells, I showed that Nur77
gfp
 is also a 
sensitive readout for TCR stimulation in iNKT cells.  Therefore, several bacterial and 
viral infections were examined for the role of antigen-dependent versus antigen-
independent activation.  These experiments showed that Nur77
gfp
 was upregulated during 
infections with a microbial antigen, and was not upregulated during an infection 
previously considered to activate iNKT cells by the cytokine driven model.  
Unexpectedly, the infectious contexts reported to require self-antigen for iNKT cell 
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activation did not upregulate Nur77
gfp
, indicating that the main driver of iNKT cell 
activation is cytokine, and thus activation is antigen-independent.  Additionally, as a 
result of the immunomodulatory capabilities of iNKT cells, iNKT cells have great 
potential for use in new therapeutics.  However, for these therapies to be effective, an 
exogenous source of iNKT cells is needed.  Therefore, I adapted the OP9-DL1 culture 
system to derive iNKT cells from hematopoietic progenitor cells in vitro.  I showed that 
the frequency of cells expressing the iNKT TCR needed to be increased in order to detect 
iNKT cells using this system.  Furthermore, I showed that the addition of IL-15 can 
enhance the percentage of cells expressing the NKT1 subset transcription factor Tbet.  
Therefore, this iNKT cell adapted OP9-DL1 culture system can be used as a new method 
to examine factors that influence iNKT cell development and to identify factors that can 
skew iNKT cell subset differentiation.  Ultimately, these experiments aided in advancing 
the understanding of iNKT cell activation and development, as well as how to harness the 
power of iNKT cells to artificially orchestrate an immune response for therapeutic use. 
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Chapter 1: Introduction 
  2 
Innate and Adaptive Immune System 
The immune system has evolved to protect the host from a variety of foreign 
invaders, such as bacteria, fungi, viruses, and parasites.  As a result of the selective 
pressure imposed by these pathogens, all multicellular organisms have an immune system 
(1).  The main function of the immune system is to efficiently recognize and eliminate 
invading pathogens, but this must be done without causing damage to the host (2).  Since 
there is enormous diversity among pathogens, the immune system has developed two 
different mechanisms for pathogen recognition: general recognition of molecular patterns 
shared by a large group of pathogens, or recognition adapted to the specific invading 
pathogen (1).  Immune cells that recognize pathogens by this first mechanism are 
considered to be part of the innate branch of the immune system, and immune cells that 
recognize pathogens by this second mechanism are considered to be part of the adaptive 
branch of the immune system.  These two branches of the immune system have different 
characteristics, which will be described below. 
The innate branch of the immune system is the first line of defense against 
invading pathogens and is found in all multicellular organisms (1). It is found in both 
plants and animals, and is therefore considered evolutionarily older than the adaptive 
branch of the immune system (2).  The innate immune response is characterized by a fast 
(within hours), non-specific response to the pathogen, and is mostly carried out by 
leukocytes from the myeloid lineage of hematopoietic cells, such as macrophages, 
neutrophils, and dendritic cells.  However, Natural Killer cells (NK), which are derived 
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from the lymphoid lineage of hematopoietic cells, are also considered to be part of the 
innate immune system.  
Innate immune cells can be characterized, in part, by their expression of germ-line 
encoded receptors called pattern recognition receptors (PRRs), which recognize distinct 
pathogen associated molecular patterns (PAMPs) (1).  PAMPs are repeating molecular 
structures found only in microorganisms, but not in host cells, thus distinguishing the 
pathogen from self.  Additionally, a PAMP is usually shared by large group of pathogens 
and is essential for the survival or pathogenicity of the microorganism, and therefore 
cannot be changed (1).  For example, a PRR can recognize the general structure of 
lipopolysaccharide (LPS), which is a structure shared by all Gram-negative bacteria, but 
not found in multicellular organisms (1).  PRRs can be expressed on the cell surface or in 
intracellular compartments of innate immune cells, or can alternatively be secreted into 
the bloodstream and other tissue fluids (1).  PRR pathogen recognition can lead to 
opsonization of the invading pathogen, activation of complement cascades, phagocytosis 
of the invading pathogen, induction of apopotosis, or activation of signaling pathways, 
such as proinflammatory signaling pathways (2). 
The best characterized class of PRR is a family of receptors known as Toll-like 
receptors (TLRs) (3).  Most mammals have between 10 to 15 different TLRs (3), which 
recognize different PAMPs.  For example, TLR4, a cell surface TLR, recognizes the 
PAMP mentioned above, LPS, in association with CD14 and MD-2, and TLR9, an 
endosomal TLR, recognizes the unmethylated dinucleotide CpG repeats found in 
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bacterial DNA (2).  Although different TLRs recognize different PAMPs, all TLRs signal 
through a conserved signaling cascade, which leads to induction of the transcription 
factor NFB (2).  NFB induction leads to the transcription of a variety of genes 
important for initiating and guiding a subsequent adaptive immune response, such as 
genes encoding cytokines, chemokines, and co-stimulatory molecules (2).  Therefore, the 
main role of the innate immune system is to rapidly clear pathogens based on general 
characteristics of the invading pathogen; however, it is also important for initiating the 
adaptive immune response, which is needed to clear the pathogen when the innate 
immune response is overwhelmed. 
In contrast to the innate branch of the immune system, the adaptive branch of the 
immune response is characterized by a slower (days as opposed to hours), very specific 
response to the invading pathogen.  Importantly, this specificity to the invading pathogen 
is maintained by the host to protect against future re-infection, which is referred to as 
immunological memory and is unique to adaptive immunity (2).  Unlike innate immunity, 
the adaptive immunity is only found in vertebrates, indicating it is evolutionarily younger 
(1, 2).  
The adaptive immune system is mainly composed of leukocytes from the 
lymphoid lineage, such as B cells and T cells.  B cells and T cells arise from a common 
hematopoietic stem cell in the bone marrow; however, B cell development occurs in bone 
marrow and T cell development occurs in the thymus.  Unlike innate immune cells, 
whose function is largely dictated by germ-line encoded receptors, B cells and T cells 
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have highly specialized antigen receptors whose rearrangement allows for very specific 
recognition of the invading pathogen (1).  These receptors are called the B cell receptor 
(BCR) for B cells or the T cell receptor (TCR) for T cells.  For this thesis, I will focus on 
the TCR.  A TCR is comprised of a heterodimeric pairing of two TCR chains.  Most 
commonly, this consists of the TCR -chain paired with the TCR -chain (+ TCR).  
As mentioned, TCRs have much greater specificity for a particular pathogen than PRRs.  
During development in the thymus, T cells acquire their antigen receptor specificity 
through a process of gene rearrangement called V(D)J recombination, which ultimately 
leads to the generation of more than 10
15
 different receptor specificities (4).  This creates 
a diverse pool of TCRs to ensure that the host will be protected from any potential 
invading pathogen.   
More specifically, a T cell’s TCR recognizes a pathogen-derived peptide in the 
context of a major histocompatibility complex molecule (pMHC).  A specialized group of 
cells, called antigen presenting cells (APCs), process pathogens into peptides for MHC 
loading and then present the pMHC on their cell surface.  However, the number of T cells 
expressing a TCR that recognizes a specific pMHC in the host is very small.  Therefore, 
to mount an effective immune response, this rare T cell must proliferate to increase the 
number of T cells expressing this antigen specific TCR.  This proliferation event is called 
clonal expansion, and occurs after the T cell meets its cognate pMHC. 
Importantly, clonal expansion is tightly controlled.  Since a diverse pool of TCRs 
is created by V(D)J recombination, it is inevitable that some of these TCRs will be 
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specific for self-antigen (self).  Although many of these T cells expressing self-reactive 
TCRs are deleted during thymic development by a process called negative selection, 
some of these T cells “escape” this control point.  Therefore, if clonal expansion occurred 
only through TCR stimulation, these “escaped” T cells would proliferate and attack the 
host, causing autoimmunity.  To prevent this, T cell clonal expansion and subsequent 
activation requires additional “cues,” which are provided by APCs (5).  APCs are cells, 
such as macrophages and dendritic cells, capable of engulfing pathogens (phagocytosis), 
as well as express a PRR like a TLR.  Therefore, in the context of an infection, an APC 
that engulfs and subsequently presents a pMHC from an invading pathogen will also be 
stimulated through its PRR to express costimulatory molecules such as CD80/CD86, and 
secrete cytokines such as IL-12 and type I Interferon, which serve as the additional 
“cues” required for clonal expansion and proper T cell activation (5).  Therefore, the APC 
presenting a stimulating pMHC will also provide the required costimulation and cytokine 
signals only in the context of an infection (1-3). 
 Although innate immunity and adaptive immunity have different roles during the 
immune response, they must cooperate together to provide the greatest protection for the 
host.  As exemplified by clonal expansion, cells involved in the innate immune response 
initiate the adaptive immune response.  Another example of this cross-talk between 
innate immunity and adaptive immunity occurs with CD1d-reactive invariant Natural 
Killer T cells (iNKT).  iNKT cells uniquely have characteristics of both innate and 
adaptive immune cells, and as a result, are considered a bridge between the innate 
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immune response and the adaptive immune response (6).  However, many questions still 
remain about how iNKT cells contribute to the immune response.  For example, the 
extent to which antigen recognition by the iNKT TCR contributes to the activation of 
iNKT cells during various infections remains to be fully elucidated, which is the subject 
of the second chapter of this thesis. 
 
Discovery of “NK T Cells” 
The isolation of a new T cell subset was reported in 1987 when three groups 
published studies identifying a subset of -TCR+ T cells that expressed intermediate 
levels of TCR, had a higher frequency of V8 expression than conventional T cells, and 
lacked expression of the co-receptor molecules CD4 and CD8 (7-9).  A few years later, 
two groups identified a subset of -TCR+ T cells that also expressed an intermediate 
level of TCR and a bias towards V8 expression, but additionally expressed the NK cell 
marker NK1.1 (10, 11).  Upon the further investigation of these subsets, it was shown 
that the CD4
-
 CD8
-
 double negative (DN) -TCR+ T cells could produce important 
immunoregulatory cytokines such as IFN and IL-4 (12), and then a year later, this same 
ability to produce immunoregulatory cytokines was reported in the subset of NK1.1
+
 -
TCR
+
 T cells (13, 14); however, at the time, it was not clear that these reports were 
describing the same subset (15).  Further characterization of the NK1.1
+-TCR+ cells 
revealed a developmental requirement for 2-microglobulin (16, 17), which led to the 
discovery that these cells are reactive to the MHC class-I-like molecule, CD1d (18).  The 
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majority of these cells were shown to have a very restricted TCR repertoire, which in 
mice, was composed of the -chain variable region 14 (V14) and the -chain joining 
region 18 (J18) paired with a restricted subset of TCR -chains (V8.2, V7 and V2) 
(19).  Additionally, this CD1d-reactive TCR repertoire was conserved in humans and 
composed of the homologous V24-J18 paired with V11 (19, 20).  Later, in 1995, the 
term “NK T cells” was used to broadly distinguish this subset of NK1.1+-TCR+ T 
cells from conventional T cells and NK cells (21).  
After the discovery that “NK T cells” are CD1d reactive, it was hypothesized that 
the antigen recognized by the “NK T” TCR was a lipid antigen (18, 22).  However, the 
first “NK T cell” lipid ligand was not conclusively identified until 1997 (23).  During a 
screen for natural anticancer compounds, the lipid galactosylceramide (GalCer), which 
is derived from the marine sponge Agelas mauritianus, was shown to prolong the survival 
of mice with B16 melanoma and enhance NK cell activation (24, 25).  These effects were 
later found to be a result of “NK T cell” activation, and thus identified GalCer as a 
strong “NK T” TCR agonist that induces “NK T cell” proliferation and rapid production 
of IFN and IL-4 (26).  After this initial discovery, further studies found that GalCer 
could be used in a CD1d tetramer to track and isolate “NK T” cells due to GalCer’s 
high affinity for the canonical “NK T” TCR (27, 28).  This was an important discovery 
because NK1.1, which was previously being used for “NK T cell” isolation, is not a 
reliable marker of “NK T cells”: not all mouse strains express NK1.1, and even in mouse 
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strains that do express NK1.1, not all “NK T cells” express NK1.1.  Therefore, “NK T 
cells” included CD1d-reactive NK1.1- cells. 
All together, these studies expanded the definition of “NK T cells” to include cells 
that express an + TCR and are reactive to lipid antigen presented by CD1d, but do not 
necessarily express NK1.1 (15, 27, 28).  However, this definition revealed two subsets 
within “NK T cells”: type I “NK T cells” which express the canonical V14-J18 TCR, 
and type II “NK T cells,” which do not express the canonical TCR (non-V14) (15, 23).  
Less is known about type II “NK T cells” which are difficult to isolate for study 
compared to type I “NK T cells,” as they cannot be isolated using the CD1d/GalCer 
tetramer (15).  Therefore, this thesis will focus on type I “NK T cells,” which will now be 
referred to as CD1d-reactive invariant Natural Killer T cells (iNKT). 
 
iNKT Cell Development and General Characteristics 
iNKT cells develop in the thymus, an organ located above the heart.  In the 
thymus, the frequency of iNKT cells is only about 0.5% (23).  Initially, iNKT cells 
follow the same developmental pathway as conventional T cells.  Both arise from a 
common hematopoietic stem cell in the bone marrow, which migrates to the thymus for 
further development.  In the thymus, these progenitor cells go through four CD8
-
 CD4
-
 
Double Negative (DN) stages before reaching the CD8
+
 CD4
+
 Double Positive (DP) 
stage.  However, at the DP stage, the iNKT cell lineage branches away from the 
conventional T cell lineage.  This occurs when rare DP thymocytes expressing the iNKT 
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TCR are positively selected by a self-lipid presented by CD1d on other DP thymocytes 
(29, 30).  Additionally, iNKT cells undergo negative selection, in which cells that express 
TCRs with too great of an affinity for the CD1d presented self-lipid, will die (31, 32).  
The identity of these self-lipids remains controversial, but may include 
isoglobotrihexosylceramide (iGb3) and/or -glucosylceramide (GlcCer) (6, 33). 
As mentioned above, iNKT cells are selected by self-lipids presented in the 
context of CD1d (18, 22).  CD1d is a non-polymorphic MHC class I-like molecule that is 
part of the CD1 family and is highly conserved among mammals (34).  It is believed that 
the CD1 family evolved to present lipids to T cells (35).  In addition to being expressed 
on DP thymocytes, CD1d is expressed mainly on dendritic cells, macrophages, and B 
cells (18, 23, 29, 36), but has also been shown to be expressed on epithelial cells (37).  
Furthermore, the cellular trafficking of CD1d has been shown to be important for the 
presentation of selecting self-lipid (23).  After biosynthesis, CD1d rapidly reaches the 
plasma membrane; however, it is subsequently internalized and recycled between the 
plasma membrane and the endosomal/lysosomal compartments (38-41).  This recycling 
was found to be dependent on a tyrosine motif in the cytoplasmic tail of CD1d, which, 
when mutated, greatly impaired iNKT cell selection (40).  This suggests that the self-lipid 
is endosome- and/or lysosome-derived, and CD1d must cycle through these 
compartments for self-lipid loading and subsequent presentation for iNKT cell selection 
(42). 
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In addition to the recognition of stimulating lipid/CD1d presented by other DP 
thymocytes, iNKT cell selection also requires homophilic interactions between signaling 
lymphocytic-activation molecule (SLAM) family members (29, 42-46).  More 
specifically, Slamf1 and Slamf6 engagement leads to the downstream recruitment of 
SLAM-associated protein (SAP) (44, 46).  SAP then interacts with the Src Kinase Fyn, 
which initiates NFB signaling through PKC and promotes iNKT cell survival (42, 47, 
48). 
After the initial selection of iNKT cells, TCR signals lead to the increased 
expression of early growth response 2 (Egr2) (49), which directly induces the expression 
of the main transcriptional regulator of iNKT cell development, PLZF (promyelocytic 
leukemia zinc finger, encoded by Zbtb16) (50-52).  PLZF has been shown to direct the 
innate-like effector differentiation of iNKT cells during thymic development, and is later 
important for full functionality and proper tissue homing (50, 51, 53, 54).  After selection 
to the iNKT cell lineage, iNKT cell development is classified into four stages.  In the first 
stage, stage 0, these earliest post-selection cells are CD24
hi
 CD44
lo
 NK1.1
-
 (29).  In the 
next stage, stage 1, these cells become CD24
lo
 CD44
lo
 NK1.1
-
 before progressing to stage 
2, in which they become CD24
lo
 CD44
hi
 NK1.1
-
 (55).  The most “mature” iNKT cells are 
found in stage 3, in which they become CD24
lo
 CD44
hi
 NKl.1
+
 (55).  However, with the 
recent discoveries of iNKT cell subsets (56), these stage divisions need to be revised. 
After PLZF expression is initiated, iNKT cells undergo further differentiation into 
three main subsets, NKT1, NKT2, and NKT17 (57-59).  These three subsets are 
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distinguished by their transcription factor profiles: NKT1 cells express Tbx21 (Tbet), 
NKT2 cells express Gata3 (GATA3), and NKT17 cells express Rorc (RORt) (56).  A 
recent report separated these three subsets into the three populations based on their 
expression of PLZF, RORt, and Tbet:  NKT1 cells are PLZFlo Tbet+, NKT2 cells are 
PLZF
hi
 Tbet
-
 RORt-, and NKT17 cells are PLZFint RORt+ (57).  This subset 
differentiation is important as it dictates the main cytokine produced by the cell after 
stimulation, and therefore influences the subsequent immune response.  NKT1 cells 
rapidly produce IFN, NKT2 cells produce IL-4, and NKT17 cells produce IL-17 (57).   
The mechanisms that drive iNKT cell differentiation into these subsets remains 
largely unknown (56).  One speculation is that the level of PLZF expression may be 
playing a role in determining each subset (56).  Alternatively, cytokines may (also) be 
influencing subset development.  For example, IL-15 may be involved in NKT1 subset 
differentiation.  Previous reports of iNKT cells in IL-15 deficient mice showed reduced 
thymic iNKT cell numbers (60, 61).  Additionally, IL-15 induced the expression of 
survival factors in thymic iNKT cells, and was shown to be involved in Tbet regulation 
during iNKT cell development (60).  Therefore, IL-15 may potentially play a role in 
driving NKT1 subset differentiation.  
Once selected, iNKT cells in mice become either CD4
+
 CD8
-
 (CD4
+
) or CD4
-
 
CD8
-
 (DN).  Interestingly, forced CD8 expression in iNKT cells resulted in their deletion 
in mice (16); however, humans have CD8
+
 iNKT cells (62).  Additionally, iNKT cells 
can express receptors typically associated with NK cells, such as NK1.1 (18), Ly49 (63), 
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CD161 (64), and NKG2D (65).  The regulation and role of these receptors in iNKT cell 
activation is not well defined, but some studies indicate that they are involved in iNKT 
cell responses to inflammation that are independent of antigenic lipid presentation (63, 
66, 67). 
After selection, iNKT cells emigrate to peripheral tissues.  In the blood and 
peripheral lymph nodes, iNKT cells make up about 0.5% of the T cell population (23).  In 
the spleen, mesenteric, and pancreatic lymph nodes, iNKT cells make up about 2.5% of T 
cells (23).  In contrast, in the liver, iNKT cells make up to 30% of the T cell population 
(23).  However, the specific locations of iNKT cells within these organs has been difficult 
to elucidate due to the technical hurdles associated with using the CD1d/GalCer 
tetramer in immunohistochemistry to accurately identify them.  
Another distinguishing characteristic of iNKT cells is their activated/memory 
phenotype during homeostasis (68).  iNKT cell express higher levels of the activation 
markers CD44 and CD69 compared to naïve conventional T cells (68), and are poised for 
rapid cytokine secretion upon stimulation (69).  This rapid cytokine secretion is 
especially prominent after stimulation with the known iNKT TCR agonist, GalCer (26).  
Upon stimulation, iNKT cells can produce a variety of cytokines such as TNF, IL-2, IL-
3, IL-5, IL-6, IL-9, IL-17, IL-21, IL-13, IL-10, TGF- and GM-CSF (48, 59, 65), but are 
most well-known for their ability to secrete IFN and IL-4 (26).  This cytokine secretion 
activates other immune cells such as NK cells, T cells, and B cells, which is called 
transactivation, and therefore influences the subsequent immune response (70). 
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Importantly, the main technique used to isolate iNKT cells is by CD1d/GalCer 
tetramer.  However, iNKT cell activation results in TCR internalization (71) and/or 
activation induced cell death (27, 72).  Therefore, the tetramer binding (CD1d/GalCer 
tet
+
) population that identifies cells as iNKT cells essentially disappears (27), making it 
difficult to definitively address questions about iNKT cell acute activation. 
As mentioned previously, iNKT cells have characteristics that are similar to both 
the innate immune response and the adaptive immune response.  For example, iNKT cells 
can very rapidly (within hours) produce cytokines upon stimulation, which is important 
for guiding the subsequent immune response.  This rapid response and ability to influence 
the adaptive immune response is reminiscent of innate immunity.  However, similarly to 
T cells in the adaptive immune response, iNKT cells undergo V(D)J recombination (19, 
42, 73) and can be activated through their TCRs upon stimulation.  Therefore, iNKT cells 
are a unique innate-adaptive hybrid that plays an important immunomodulatory role (70).  
However, as compared to conventional T cells, the invariant iNKT TCR limits the 
capacity of iNKT cells to respond to a diverse repertoire of antigens.  Interestingly, 
despite this restricted capacity for antigen recognition, iNKT cells are implicated in wide 
range of pathogenic infections (70), leading to the question of how iNKT cells are 
activated during such a variety of infectious contexts. 
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iNKT Cell Activation During Infections 
Currently, there are three main models of iNKT cell activation during infection: 
1) activation requiring microbial antigen; 2) activation solely driven by cytokines; or 3) 
activation requiring self-antigen (74). 
For the microbial antigen driven model of iNKT cell activation, previous reports 
have shown exogenous glycolipid antigens produced by infectious agents can activate 
iNKT cells through their TCR, and this activation is CD1d-dependent (75-79).  For 
example, iNKT cells are activated by glycosylated diacylglycerol antigens from 
Streptococcus pneumoniae (77, 78) or from Borrelia burgdorferi (80), by 
glycosphingolipids (GSLs) with an -linked glucuronic or galacturonic acid from 
Sphingomonas paucimobilis (75, 76), or by phosphatidylinositol mannoside from 
mycobacterial membrane (81).  Additionally, asperamide B, a GSL derived from the 
fungus Aspergillus fumigatus, activated iNKT cells through a CD1d-dependent 
mechanism (82).  During these microbial infections, APCs present microbial-derived 
antigenic lipid, which when recognized by the iNKT TCR, causes iNKT cell activation.  
Once activated, iNKT cells secrete cytokines, leading to the transactivation of other 
immune cells and contributing to pathogen clearance (70). 
iNKT cells are also able to rapidly produce cytokines during a variety of 
infections where the pathogen is not known to produce exogenous antigenic lipid.  
Similarly to some situations with T cells and CD4 and CD8 memory T cells, which 
can become activated independently of antigen receptor stimulation and is sometimes 
  16 
referred to as non-cognate activation (83-87), iNKT cell activation in antigen independent 
contexts are thought to be solely driven by cytokines secreted by APCs (74).  For 
example, this cytokine driven model has been proposed to explain iNKT cell activation 
during viral infections such as mouse cytomegalovirus (MCMV) (88).  After MCMV 
infection, iNKT cells demonstrated an activated phenotype and produced IFN, which 
resulted from APC secretion of IL-12 and IL-18 (88).  There was little or no effect on 
IFN production when CD1d was blocked or deleted, indicating that IL-12 and IL-18 
were the main drivers of iNKT cell activation during this infection (88).  
However, this cytokine driven model is not thought to occur during all infections 
that lack exogenous antigenic lipid.  Instead, an alternative model of iNKT cell activation 
dependent on TCR stimulation is proposed to occur (70).  More specifically, it is 
proposed that iNKT cell activation is induced, at least in part, as a result of stimulation of 
TLRs on APCs, which not only causes the secretion of cytokines such as IL-12 or type I 
IFN, that participate in the iNKT cell activation process, but which also causes increased 
synthesis and presentation of an antigenic endogenous lipid by APCs (89-91).  This 
process is sometimes referred to as indirect activation because rather than providing the 
antigen, the bacteria are inducing the synthesis of both a stimulatory antigen and 
cytokines by host APCs (74).  Two GSLs, iGb3 and GlcCer, are reported self-lipids that 
are potential candidates for the antigenic endogenous lipid in this model (6, 33).  
However, this identification remains speculative, as the full spectrum of antigenic self-
lipids has yet to be identified. 
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Notably, this indirect method of iNKT TCR stimulation is controversial.  The 
main support for this model stems from Salmonella typhimurium (S. typhimurium) 
infection data.  S. typhimurium is a Gram-negative LPS-positive pathogen not reported to 
contain an iNKT TCR stimulating microbial lipid antigen, but activates iNKT cells to 
produce IFN during infection.  More specifically, Brigl et al. reported that after S. 
typhimurium infection, the percentage of iNKT cells producing IFN was decreased in 
infected animals given CD1d blocking antibody, indicating that iNKT cell activation was 
at least partially dependent on CD1d (92).  Further support for this model was reported by 
Darmoise et al.  In this report, it was found that TLR stimulation led to the inhibition of 
the enzyme -galactosidase A (-Gal A) (89).  -Gal A was proposed to convert a 
stimulatory lipid to a non-stimulatory lipid, and thus the inhibition of this enzyme 
resulted in the increased accumulation, and therefore presentation, of a stimulatory lipid 
for iNKT cell activation (89).  When -Gal A deficient bone marrow derived dendritic 
cells (BMDC) were injected into wild type mice, iNKT cells expressed higher levels of 
the activation marker CD69 and exhibited a decreased population of CD1d/GalCer tet+ 
cells, which was used as an indication of CD1d-dependent stimulation of iNKT cells in 
vivo (89).  Therefore, APC TLR stimulation leads to the presentation of an antigenic 
endogenous lipid that activates iNKT cells (89). 
Further understanding of the indirect activation model, whereby iNKT cells are 
activated by antigenic endogenous lipid, is important as it may also be occurring in 
noninfectious diseases such as type I diabetes and asthma (93-95).  Greater mechanistic 
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understanding of how iNKT cells are activated in the absence of exogenous antigenic 
lipid might also elucidate novel ways to control iNKT cells during infections.  However, 
one challenge to this greater understanding is that it remains difficult to distinguish TCR-
mediated from non-TCR mediated iNKT cell activation.  Current studies use CD69 
upregulation, cytokine production, and reduced recovery of iNKT cells using tetramers, 
which is presumed to be secondary to TCR internalization, as markers of iNKT cell 
activation.  However, all of these features can also be a consequence of non-TCR 
mediated activation.  Therefore, a more sensitive method is needed to study the role of 
antigen receptor stimulation in iNKT cell activation during infections in vivo.  Recently, a 
novel Nur77
gfp
 BAC transgenic mouse model was developed, which upregulated GFP in 
T cells in response to antigen receptor stimulation but not inflammatory signals (43).  
Thus, the aim of Chapter 2 of this thesis was to determine the role of TCR stimulation 
during antigen-dependent versus -independent iNKT cell activation using the Nur77
gfp
 
transgenic mouse.  
 
Nur77
gfp
 Transgenic Mouse 
 Nur77, also known as Nr41a, is an orphan steroid hormone nuclear receptor and 
an immediate early gene upregulated by TCR stimulation in thymocytes and T cells (96).  
It is regulated by nuclear factor of activated T cells (NFAT), and can be involved in 
multiple parts of the TCR signaling cascades (97-99).  Although the function of Nur77 
has not been fully elucidated, it is thought to play a role in thymocyte apoptosis (100-
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102).  Interestingly, in a microarray comparing thymocytes undergoing either positive 
selection or negative selection, Nr41a showed a two-fold increase in expression in 
thymocytes undergoing positive selection in comparison to a ten-fold increase in 
expression in thymocytes undergoing negative selection (103).  This differential 
expression indicated that a Nur77 reporter mouse may be useful for examining TCR 
signal strength.  
Therefore, a Nur77
gfp
 transgenic (Tg) mouse was developed in which GFP was 
inserted into the Nur77 locus in a bacterial artificial chromosome (43).  Using Kb/OVA-
specific OT-I TCR transgenic mice and altered peptide ligands with known affinity for 
the OT-I TCR, the GFP expression levels in T cells from OT-I Nur77
gfp
 Tg mice were 
shown to reflect the TCR stimulatory strength of the altered peptide ligand (43).  
Therefore, GFP expression was a sensitive readout for TCR affinity, as even the lowest 
affinity peptide variant or a self-peptide was shown to induce GFP above background 
levels.  Importantly, GFP expression was specific for TCR stimulation:  stimulation by 
cytokine alone had no effect on GFP expression in T cells (43).  Therefore, the Nur77
gfp
 
Tg mouse was shown to be a sensitive reporter of TCR stimulation in T cells (43). 
In addition to examining T cells, iNKT cells were examined in the initial 
characterization of the Nur77
gfp
 Tg mouse.  Although GFP expression in iNKT cells in 
the periphery was very low, GFP expression was upregulated after stimulation with the 
known strong agonist, GalCer (43).  Additionally, iNKT cell GFP levels were examined 
during development.  As expected, the earliest post-selection iNKT cell exhibited the 
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highest level of GFP (43), which comports with the idea that iNKT cells are selected by a 
self-lipid that stimulates the iNKT TCR as described above.  Together, these data 
indicated that the Nur77
gfp
 Tg mouse may be a useful tool to examine antigen-dependent 
versus antigen-independent models of activation in iNKT cells. 
 
iNKT Cells in Noninfectious Diseases 
 In addition to contributing to the immune response during infections, iNKT cells 
have been shown to be important in a variety of disease contexts, such as in asthma, 
autoimmune disease, and cancer (93).  For example, iNKT cell deficient mice failed to 
develop allergen-induced airway hyperreactivity (AHR), indicating iNKT cells are 
required for pathogenesis (104).  Furthermore, IL-4 and IL-13 produced by iNKT cells 
were shown to be essential for allergen-induced AHR development (105).  However, in 
the ozone-induced AHR model of asthma, the production of IL-17 by iNKT cells was 
required for pathogenesis (95, 106).  Interestingly, the production of IFN after the 
systemic administration of the strong iNKT cell agonist GalCer inhibited asthma 
pathogenesis in an OVA-induced AHR model (107, 108). 
In addition to asthma, iNKT cells have been implicated in multiple autoimmune 
diseases, such as type I diabetes, experimental autoimmune encephalomyelitis and 
multiple sclerosis (EAE/MS), and systemic lupus erythematosus (SLE) (109).  For type I 
diabetes, studies were performed in NOD mice, which spontaneously develop disease.  
Interestingly, the iNKT cell population in these mice is numerically and functionally 
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decreased (110, 111).  Furthermore, in CD1d-deficient NOD mice, the onset of disease 
was accelerated and the incidence of disease was increased (112, 113).  However, young 
NOD mice that received an adoptive transfer of lymphocytes enriched for iNKT cells 
failed to develop diabetes (111).  This suppressive influence of iNKT cells was associated 
with IL-4 production, implicating that a shift from a TH1 cytokine bias (i.e., IFN) 
toward a TH2 cytokine bias (i.e., IL-4) conferred protection against disease (94, 114).  
Interestingly, it was also found that NOD mice treated with GalCer exhibited delayed 
disease onset and reduced incidence of disease (115).  Even when GalCer treatment was 
initiated after the onset of invasive insulitis, disease severity was reduced (113).  In 
contrast, the role of iNKT cells in SLE and EAE/MS is less defined.  Interestingly, in 
both diseases, iNKT cells may have a neutral or protective function before disease onset, 
but after disease onset, may play a pathogenic role (109). 
In cancer, iNKT cells are involved the anti-tumor response (116).  In one study, 
iNKT cell deficient mice indicated that iNKT cells are required for protection against 
spontaneous tumors initiated by MCA, a chemical carcinogen (117, 118).  In a B16 
melanoma model, iNKT cells were shown to be required for IL-12 mediated tumor 
rejection (119).  Although it is currently unknown how iNKT cells are activated in tumor 
environments (116), other studies have shown that activation of iNKT cells using 
GalCer will further boost the antitumor response.  For example, IFN produced by 
GalCer activated iNKT cells was protective against B16 melanoma metastases (120).  
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Additionally, activated iNKT cells directly contributed to antitumor cytotoxicity in a 
perforin-dependent manner (121). 
Therefore, clinical trials using GalCer to activate iNKT cells were initiated (122, 
123).  Despite being well-tolerated, GalCer treatment did not effectively boost the anti-
tumor response (122, 123).  This may be due to observations that cancer patients have a 
decreased number of iNKT cells compared to the number of iNKT cells in healthy 
volunteers (124, 125).  Furthermore, the iNKT cells from these patients exhibited 
decreased proliferation and cytokine production after ex vivo stimulation (126), indicating 
the remaining iNKT cells have reduced functional capacities.  The reason for the decrease 
in iNKT cell number and function is not known, but could be a result of autoantigen 
presented by tumors causing activation induced cell death and/or anergy, or suppression 
of iNKT cells by Tregs (127, 128).  Thus, for GalCer treatment, or any iNKT cell based 
therapy, to be effective, the number of functional iNKT cells needs to be supplemented. 
One way this can be achieved is by an exogenous source of iNKT cells.  Therefore, the 
derivation of iNKT cells from hematopoietic progenitor cells in vitro was the aim of 
Chapter 3 of this thesis. 
 
OP9-DL1 Culture System 
Previous work showed that the bone marrow stromal cell line, OP9, can support 
the differentiation of hematopoietic progenitor cells (HPCs) into multiple lineages, such 
as B cells, but it did not support T cell development (129, 130).  This inability to support 
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T cell development was hypothesized to be, at least partially, due to the absence of Notch 
signaling in this system (131).  Notch signaling is essential for determining whether 
lymphocyte progenitors adopt a T cell fate over a B cell fate (131, 132), and is also 
required throughout T cell development, although the specific details of these 
requirements are still incompletely understood.  Therefore, when OP9 cells were 
retrovirally transduced to express the Notch ligand Delta-like-1 (DL1), these OP9-DL1 
cells supported T cell development from HPCs (131).  Additional studies using OP9-DL1 
cells showed that T cell development could also be induced in embryonic stem cells 
(ESCs) (133), progenitor cells from human umbilical cords (134), and human bone 
marrow-derived progenitor cells (134). 
During normal T cell development, lymphoid progenitor cells leave the bone 
marrow and migrate to the thymus.  After entering the thymus, these progenitors are 
stimulated through the receptor Notch1, which signals T cell lineage commitment and 
causes these cells to undergo cell proliferation for about a week.  Because these cells do 
not express the co-receptors CD8 or CD4, they are called DN thymocytes, and progress 
through four DN stages before becoming DP thymocytes.  The four DN stages are 
identified by the differential expressions of the markers CD44 and CD25, in which DN 
stage 1 cells are CD44
+
 CD25
-
, DN stage 2 cells are CD44
+
 CD25
+
, DN stage 3 cells are 
CD44
lo
 CD25
+
, and DN stage 4 cells are CD44
-
 CD25
-
 (135).  During the DN stages, the 
TCR -chain undergoes rearrangement and is subsequently paired with a surrogate pre-T 
receptor -chain, which leads to the arrest of -chain rearrangement and the expression 
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of CD8 and CD4, thus entering the DP stage.  At the DP stage, -chain rearrangement 
occurs for the production of the + TCR.  Importantly, after a productive + TCR is 
found, it is tested for the ability to recognize self-pMHC presented by thymic epithelial 
cells.  TCRs that recognize self-pMHC continue to mature, which is called positive 
selection, and ensures that a productive TCR that is MHC restricted was assembled (136).  
TCRs that fail to recognize self-pMHC die.  These thymocytes are also tested for the 
strength of self-pMHC TCR recognition.  If the affinity of this interaction is too high, the 
cells will undergo apoptosis, which is called negative selection and ensures that self-
reactive TCRs do not enter the periphery (136).  At the last stages of development, these 
cells express high levels of TCR and cease to express one of the co-receptor molecules to 
become either CD4
+
 single positive (SP) or CD8
+
 SP.  Only cells with TCRs that survive 
both positive and negative selection will fully mature and emigrate to the periphery.  
During T cell development supported by OP-DL1 cells, the HPCs undergo the 
same stages of initial T cell development (131).  At the DN stages, they express the same 
CD44 and CD25 markers and rearrangement of the TCR- chain as DN thymocytes 
before progressing to the DP stage (131).  However, in in vitro cultures, the thymic 
epithelial cells required for positive selection and negative selection are absent.  
Therefore, positive selection and negative selection cannot occur, and mature T cells 
should not develop.  However, CD8SP T cells were found in these cultures, and were 
considered “functional” based upon their ability to produce IFN after stimulation with 
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plate bound CD3 and CD28 antibodies (131, 133).  Despite this, the classification of 
these cells as “functional” CD8 T cells as well as their utility remains controversial. 
 Although iNKT cells go through the same initial developmental pathway as T 
cells, they do not go through the same thymic epithelial cell-dependent positive and 
negative selection.  Instead, iNKT cells go through different positive and negative 
selection processes at the DP stage, which are dependent on DP thymocytes (31, 137).  
Since iNKT cell development is dependent on DP thymocytes, and the OP9-DL1 culture 
system faithfully induces T cell development up to the DP stage, the OP9-DL1 culture 
system could potentially be used to derive a source of supplemental iNKT cells for iNKT 
cell based therapies. 
 Three previous studies have examined this possibility (47, 138, 139).  More 
specifically, nuclear transfer from mature iNKT cells (with a V14-J18 rearranged 
TCR) were used to create ESC lines, which were then cultured with OP9-DL1 cells and 
gave rise to iNKT cells (139).  The same group also showed splenic iNKT cells could be 
reprogrammed into induced pluripotent stem cells (iPSCs), which gave rise to iNKT cells 
when cultured with OP9-DL1 (138).  Additionally, a different group showed that iNKT 
cells could be derived from HPCs, but the transient nature of the iNKT cell population 
and difficulty with reproducing this data, makes this finding questionable (47). 
Although these previous reports showed successful derivation of iNKT cells using 
the OP9-DL1 culture system, they did not examine transcription factors to identify which 
subsets were being produced.  This distinction is important because the transcription 
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factors (Tbet, RORt, and GATA3) that distinguish the iNKT subsets also dictate the 
cytokine produced by iNKT cells upon stimulation, which affects the subsequent immune 
response (57).  This is especially important for the use of these iNKT cells in iNKT cell 
based therapies.  For example, IFN is essential for the antitumor response (116), and 
therefore NKT1 cells would be the most beneficial subset for this therapeutic use.  Hence, 
Chapter 3 of this thesis also sought to define the culture conditions that result in the 
differentiation of the NKT1, NKT2, and NKT17 subsets. 
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Chapter 2: Antigen-dependent Versus -independent Activation 
of iNKT Cells During Infection 
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CD1d-reactive invariant natural killer T cells (iNKT) play a vital role in 
determining the kinetics, extent, and characteristics of an immune response. Insight into 
their activation by infectious agents is therefore crucial for the general understanding of 
how iNKT cells contribute to immune responses.  Previous reports suggest that iNKT cell 
activation during infection can be: 1) solely driven by cytokines from innate immune 
cells; 2) require microbial antigen; or 3) require self-antigen. In this study, we examined 
the role of antigen receptor stimulation in iNKT cells during several bacterial and viral 
infections in vivo.  To test for antigen receptor signaling, Nur77
gfp
 BAC transgenic mice, 
which upregulate GFP in response to antigen receptor stimulation but not inflammatory 
signals, were analyzed.  iNKT cells from reporter mice infected with mouse 
cytomegalovirus (MCMV) produced IFN, but did not upregulate GFP, consistent with 
their reported CD1d-independent activation, but IL-12 dependent mode of activation.  
However Streptococcus pneumoniae and Sphingomonas paucimobilis, two bacteria 
known to produce lipid antigens for iNKT cells, induced GFP expression and cytokine 
production.  In contrast, although Salmonella typhimurium (S. typhimurium) was 
proposed to induce the presentation of antigenic self-lipid, iNKT cells produced IFN, 
but did not upregulate GFP after infection in vivo.  Even in CD1d-deficient hosts, iNKT 
cells were still able to produce IFN after S. typhimurium infection.  Furthermore, while it 
has been proposed that antigenic endogenous lipid presentation is a result of Toll-like 
receptor (TLR) stimulation of antigen presenting cells, injection of different TLR 
agonists led to iNKT cell IFN production but not increased GFP expression.  These data 
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indicate that robust iNKT cell responses to bacteria as well as viruses can be obtained in 
the absence of antigenic iNKT T cell receptor stimulation. 
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Introduction 
CD1d-reactive invariant Natural Killer T cells (iNKT cells) are a distinct lineage 
of  T lymphocytes with an invariant T cell antigen receptor (TCR) composed in mice 
of the -chain variable region 14 (V14) and the -chain joining region 18 (J18) paired 
with a restricted subset of TCR- chains (19).  As a result of this TCR expression, iNKT 
cells are able to recognize several types of glycolipid antigens in the context of CD1d, a 
non-classical major histocompatibility class I (MHC-I)-like antigen presenting molecule.  
Upon glycolipid presentation, and most famously with the strong agonist 
galactosylceramide (GalCer), iNKT cells are able to rapidly produce cytokines such as 
IFN and IL-4 (26).  This rapid cytokine production contributes to the recruitment and 
activation of other cell types during an immune response, which has been shown to 
influence a variety of diseases, including cancer (119), autoimmunity (140, 141), and 
pathogenic infection (127).  Therefore, insight into their activation is crucial for the 
general understanding of how iNKT cells contribute to immune responses. 
One area that remains to be fully elucidated is the extent to which antigen 
recognition by the iNKT TCR contributes to the activation of iNKT cells during various 
infections.  Previous reports have shown that iNKT cells can be activated through the 
TCR by certain infectious agents that produce glycolipid antigens (75-79).  For example, 
iNKT cells are activated by glycosylated diacylglycerol antigens from Streptococcus 
pneumoniae (S. pneumoniae) in a CD1d-dependent manner (78).  Furthermore, iNKT 
deficient mice infected with S. pneumoniae have significantly reduced survival compared 
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to infected wild type mice (77).  In addition, Sphingomonas paucimobilis (S. 
paucimobilis), which is a Gram-negative bacteria that does not express LPS, produces 
glycosphingolipids (GSLs) with an -linked glucuronic or galacturonic acid that are able 
to activate iNKT cells (75, 76, 142).  More specifically, it was shown that these GSLs 
activate iNKT cell proliferation and cytokine secretion, which was dependent on CD1d 
(79). 
However, iNKT cells are able to rapidly produce cytokines during a variety of 
infections where the pathogen is not known to produce an exogenous stimulating lipid 
(79, 92), raising the question of how iNKT cells are activated to rapidly produce 
cytokines.  It was previously proposed that during these types of infections, iNKT cell 
activation occurs partly in response to the presentation of an endogenous lipid capable of 
stimulating the iNKT TCR (79, 89, 92).  During these types of infections, iNKT cell 
responses are induced, at least in part, as a result of stimulation of Toll-like receptors 
(TLRs) on antigen presenting cells (APCs), which not only causes the secretion of 
cytokines, such as IL-12 or type I IFN, that participate in the iNKT cell activation 
process, but which also causes increased synthesis and presentation by the APCs of an 
antigenic endogenous lipid (89-91).  This process is sometimes referred to as indirect 
activation, because rather than providing the antigen, the bacteria are inducing the 
synthesis of both a stimulatory antigen and cytokines by host APCs.  Although the full 
spectrum of endogenous stimulatory lipids remains to be identified, and their relative 
importance remains to be conclusively assessed, two GSLs, isoglobotrihexosylceramide 
  32 
(iGb3) and -D-glucopyranosylceramide (GlcCer) are known to be self-lipids (6, 33, 
89).  This indirect method of iNKT TCR stimulation is proposed to occur during 
Salmonella typhimurium (S. typhimurium) infection, which is a Gram-negative 
lipopolysaccharide (LPS)-positive pathogen not reported to contain an iNKT TCR 
stimulating microbial lipid antigen (79, 92).  Brigl et al. reported that after S. 
typhimurium infection, the percentage of iNKT cells producing IFN was decreased in 
infected animals given CD1d blocking antibody, indicating that iNKT cell activation is at 
least partially dependent on CD1d (92). 
Yet it is clear that in some situations T lymphocytes, such as T cells and CD4 
and CD8 memory T cells, become activated independently of antigen receptor 
stimulation, which is sometimes referred to as non-cognate activation (83-87).  Therefore, 
it is possible that certain microorganisms are able to activate iNKT cells independently of 
their TCR (88, 143).  This antigen-independent model has been proposed to explain 
iNKT cell activation during infection with mouse cytomegalovirus (MCMV), which is 
not reported to contain an iNKT TCR stimulatory lipid (88).  Upon infection with 
MCMV, iNKT cells demonstrated an activated phenotype and produced IFN.  This 
activation resulted from APC secretion of IL-12 and IL-18, and there was little or no 
effect on IFN production when CD1d was blocked or deleted (88, 144). 
Further understanding of the indirect activation mode, whereby iNKT cells are 
activated by antigenic endogenous lipids, is important as it may be occurring in diseases 
such as type I diabetes and asthma (93-95).  Greater mechanistic understanding might 
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also provide a profound way to control iNKT cells during infections.  However, one 
challenge to greater understanding is that it remains difficult to distinguish TCR-
mediated from non-TCR mediated activation.  The activation parameters typically used in 
the study of iNKT cells are CD69 upregulation, cytokine production, and reduced 
recovery of iNKT cells using tetramers presumed to be secondary to TCR internalization.  
All of these features, however, can also be a consequence of non-TCR mediated 
activation.  In this study, we examined the role of antigen receptor stimulation in iNKT 
cell activation during infections in vivo using Nur77
gfp
 BAC transgenic mice, which 
upregulate GFP in response to antigen receptor but not inflammatory signals (43).  Such 
mice were infected and examined for cytokine production and GFP expression as 
indicators of iNKT cell activation and iNKT TCR stimulation, respectively.  
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Results 
iNKT Cells from the Nur77
gfp
 Reporter Mouse Upregulate GFP in Response to 
Antigenic Lipids 
This study sought to demonstrate iNKT cell TCR stimulation by antigen during 
various infections.  However, markers of activation used previously, including CD69 
upregulation, TCR downregulation, and cytokine production, can all be induced by 
stimuli independent of antigen receptor engagement.  Previous work showed that 
Nur77
gfp
 BAC transgenic mice, which encode GFP in the locus of an immediately early 
gene downstream of the TCR—Nur77 (Nr4a1), expressed GFP in T lymphocytes only 
after antigen receptor stimulation, and not after inflammatory signals, cytokines, or 
stimuli that promote cell survival or trafficking (43).  It was also shown that iNKT cells 
in this reporter mouse exhibited a very low level of GFP in the periphery at steady state, 
suggesting that iNKT cells are not continuously receiving stimulation through their TCR 
(43).  However, when injected with the potent TCR agonist GalCer, iNKT cells greatly 
increased expression of GFP (43).  Therefore, we used the Nur77
gfp
 mouse to examine 
iNKT TCR activation in vivo. 
Using OT-I TCR transgenic CD8 T lymphocytes, the Nur77
gfp
 reporter was 
shown to respond to very weak TCR stimuli, such as those that support positive selection 
or are incapable of inducing the proliferation of mature T cells (43).  Therefore we sought 
to test the sensitivity of GFP upregulation after iNKT cell TCR stimulation.  Most 
antigenic lipids have lower affinities for the iNKT TCR compared to GalCer (145, 146), 
  35 
and we tested OCH, -D-glucopyranosylceramide (GlcCer), and 
isoglobotrihexosylceramide (iGb3), in addition to GalCer.  GalCer is a 
glycosphingolipid derived from a marine sponge, and has been shown to strongly activate 
iNKT cells to produce both IL-4 and IFN upon stimulation (26).  GalCer has also been 
reported to have the strongest affinity for the iNKT TCR (145).  OCH is an analog of 
GalCer, and is reported to also strongly activate iNKT cells, albeit with a slightly 
weaker affinity for the iNKT TCR than GalCer (145, 147).  iGb3, and more recently 
GlcCer, were identified as putative endogenous self-lipids capable of activating iNKT 
cells through the TCR (6, 33).  iGb3 is a weak activator of iNKT cells with a much lower 
affinity for the iNKT TCR than GalCer, in the low M range compared to as low as 
11nM for complexes of GalCer bound to CD1d (148, 149).  GlcCer, when loaded into 
CD1d tetramers, is at least capable of binding to a proportion of iNKT cells, suggesting 
that it is a stronger ligand than iGb3, although an affinity measurement per se has not 
been reported (6).  
We tested the ability of these lipids to activate the iNKT TCR by pulsing bone 
marrow derived dendritic cells (BMDC), and then intravenously injecting them into 
Nur77
gfp
 mice.  After 18 hours, iNKT cells were isolated and examined directly ex vivo 
by flow cytometry for GFP upregulation.  All four lipids induced an upregulation of GFP 
as compared to iNKT cells from a control mouse injected with unpulsed BMDC (Figure 
2-1).  GalCer consistently induced the strongest increase, although OCH induced only 
slightly less. Of the putative antigenic self-lipids, GlcCer induced a higher upregulation 
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of GFP than iGb3.  CD69 was also upregulated, showing the same order of expression 
(GalCer > OCH > Glc > iGb3) (Figure 2-1), although its use as a marker of iNKT 
TCR stimulation during infections is limited by the fact that it can also be upregulated by 
inflammatory stimuli (43, 150).  These results suggest that in the Nur77
gfp
 mouse, GFP 
expression is a sensitive tool for assessing iNKT TCR stimulation. 
Figure 2-1.  iNKT cells upregulated GFP in response to various antigenic lipids, 
including self-lipids.  Expression of GFP (top) and CD69 (bottom) by splenic iNKT cells 
from B6 Nur77
gfp
 mice 18 h after injection with bone marrow-derived unpulsed DCs 
(cntrl) or BMDCs pulsed with GalCer, OCH, or the self-lipids GlcCer or iGb3 as 
described in Materials and Methods.  Histograms are representative of eight independent 
experiments.  Average relative mean fluorescence intensity (MFI) of GFP (normalized to 
that in CD4 T cells in each experiment) is indicated. 
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MCMV Infection Does Not Stimulate iNKT Cells Through Their TCR 
MCMV does not contain a stimulatory lipid that activates the iNKT TCR; 
however, MCMV has been shown to activate iNKT cells during infection in vivo, as 
demonstrated by increased CD25 and CD69 expression, and by IFN production detected 
by intracellular cytokine staining as early as 24 hours after infection (88).  This activation 
is thought to be predominantly a result of IL-12 secretion and IL-18 and/or type I IFN 
secretion from APCs that were activated through TLR9 (144, 151).  Importantly, there 
was little to no effect on iNKT cell IFN production in experiments where CD1d was 
blocked and/or deleted (88).  Since CD1d-mediated antigen is not considered a key-
player in the MCMV-induced activation of iNKT cells, we tested this putatively 
cytokine-mediated model of iNKT cell activation in vivo using the Nur77
gfp
 mouse.  
Similar to previous reports, iNKT cells from Nur77
gfp
 mice infected with MCMV showed 
a statistically significant increase in the percentage of hepatic iNKT cells that produced 
IFN 36 hours post infection (Figure 2-2B).  Interestingly, the level of GFP expression 
remained the same at all time points examined, suggesting that iNKT cells did not receive 
TCR stimulation during MCMV infection (Figure 2-2A), and confirming that other 
inflammatory stimuli produced during infections do not cause GFP upregulation (43). 
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Figure 2-2.  MCMV infection induced iNKT cell cytokine production, but not GFP 
expression.  Nur77
gfp
 B6 mice were infected with MCMV i.p., and tet
+
 liver iNKT cells 
were analyzed by flow cytometry 36 h later for GFP expression (A) and IFN production 
(B).  Results show uninfected (left), MCMV infected (middle) and GalCer treated 
animals 3 h after injection (right).  Data are representative of two independent 
experiments, with at least three animals per time point.  The histogram in (B) shows GFP 
expression of the IFN- iNKT cell population versus the IFN+ iNKT cell population 
from an animal 36 h post infection. In graphs, each dot represents one mouse (uninfected 
n = 6; 12 h post infection n = 3; 24 h post infection n = 3; 36 h post infection n = 6; 3 h 
post GalCer injection n = 3).  **P = 0.0026, percentage uninfected IFN+ iNKT cells 
versus percentage 36 h post infection IFN+ iNKT cells (unpaired two-tailed t-test). 
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S. pneumoniae and S. paucimobilis Stimulate iNKT Cells Through Their TCR 
 We next infected Nur77
gfp
 mice with microbes that are known to produce lipid 
antigens that activate iNKT cells (75, 78).  S. pneumoniae is an extracellular Gram-
positive pathogen, which produces glycosylated diacylglycerol antigens (77, 78).  These 
antigens are highly abundant in the bacteria, they can stimulate the iNKT TCR, and iNKT 
cells were shown be important for clearance and host survival (78).  S. paucimobilis is a 
Gram-negative bacteria that does not produce LPS, but does produce a GSL with an -
linked glucuronic acid, which also has been shown to directly stimulate the iNKT TCR 
when presented by CD1d (75, 76).  S. paucimobilis also produces another GSL with a 
tetrasaccharide head group, that is either weakly antigenic (152) or not antigenic (153). 
 We systemically infected Nur77
gfp
 mice with S. pneumoniae by intravenous 
injection, harvested iNKT cells 6 or 20 hours later, and analyzed cytokine by intracellular 
staining directly ex vivo without re-stimulation (Figure 2-3A).  As expected, iNKT cells 
produced IFN (Figure 2-3B) and upregulated CD69 (not shown).  Consistent with a 
TCR-dependent activation mode, the expression of GFP increased in iNKT cells as well 
(Figure 2-3A).  This increase was statistically significant compared to the uninfected 
control mice, but was well below that seen after injection of GalCer, indicating that 
although lipids are presented during microbial infections that are able to activate iNKT 
cells through their TCR, they are weaker agonists than GalCer.  This result is consistent 
with previous reports that lipid antigens from S. pneumoniae presented by CD1d have an 
affinity for the iNKT TCR in the low M range, compared to the low nM range for 
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GalCer complexes with CD1d (78, 154).  Notably, the GFP level was higher in the 
subset of iNKT cells producing IFN, suggesting that a TCR signal activated cytokine 
production. 
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Figure 2-3.  S. pneumoniae infection induced cytokine production and GFP 
expression.  Nur77
gfp
 B6 mice were infected with S. pneumoniae i.v., and tet
+
 iNKT cells 
were analyzed by flow cytometry for GFP expression (A) and IFN production (B). 
Results shown are from uninfected mice (left), mice 6 h post S. pneumoniae infection 
(middle) and GalCer treated animals 2.5 h after injection (right).  The histogram in (B) 
shows GFP expression in the IFN- iNKT cell population versus the IFN+ iNKT cell 
population from 20 h post infection.  Data show representative dot plots of two 
independent experiments with six animals per time point. For the percentage of GFP
+
 
iNKT cells graph (A), ***P = 0.0006, uninfected versus 6 h post infection; and ***P = 
0.0007, uninfected versus 20 h post infection.  For the percentage of IFN-+ iNKT cells 
graph (B), *P = 0.0478, uninfected versus 6 h post infection; *P = 0.0483, uninfected 
versus 20 h post infection (all using unpaired two-tailed t-test). 
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Similarly, iNKT cells upregulated GFP expression 18 hours after infection with S. 
paucimobilis (Figure 2-4A). This increase was statistically significant compared to the 
uninfected controls, but again was well below that seen after injection of GalCer  
(Figure 2-4A), which is consistent with previous reports (75). For these experiments we 
used Nur77
gfp
/KN2 mice that have a human CD2 (hCD2) gene engineered into one allele 
of the IL-4 locus, because it was shown that S. paucimobilis GSLs also induce IL-4 
production by iNKT cells (75). S. paucimobilis infection resulted in the production of IL-
4 by iNKT cells, as judged by increased hCD2 staining, which interestingly was 
primarily produced by cells that had upregulated GFP (Figure 2-4B), again supporting the 
idea that a TCR signal activates cytokine production in iNKT cells.  Overall, these data 
indicate that S.pneumoniae and S. paucimobilis infections, in which the bacteria have 
glycolipid antigens capable of stimulating the iNKT TCR, activate iNKT cells through 
TCR stimulation. 
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Figure 2-4.  S. paucimobilis infection induced cytokine production and GFP 
expression.  IL-4 reporter (KN2) Nur77
gfp
 B6 mice were infected with S. paucimobilis 
i.v., and tet
+
 iNKT cells were analyzed by flow cytometry 18 h post infectionfor GFP (A) 
and human CD2 expression (B).  Histograms in (A) show GFP expression for uninfected 
(left), 18 h infected (middle) and 3 h GalCer injected (right) animals.  The histogram in 
(B) shows GFP expression on the hCD2
-
 iNKT cell population versus the hCD2
+
 iNKT 
cell population from an animal 18 h post infection.  Data show representative dot plots of 
two independent experiments with four to six animals per time point.  **P = 0.0082, 
uninfected versus 18 h post infection (unpaired two-tailed t-test). 
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S. typhimurium Infection Does Not Stimulate iNKT Cells Through Their TCR 
Having analyzed a cytokine-mediated model of activation and two direct 
activation models, we next analyzed a third proposed model of iNKT cell activation.  In 
this case, we infected mice with a microbe that has not been shown to produce a 
microbial antigen for iNKT TCR stimulation, but putatively causes APCs to present an 
antigenic endogenous self-lipid that stimulates the iNKT TCR, namely S. typhimurium 
(79, 92).  S. typhimurium is a Gram-negative LPS-positive pathogen in which a microbial 
lipid antigen has not been detected, but which causes the activation of iNKT cells that has 
been shown to be partially CD1d dependent, but which is also dependent on MyD88 
expression by the APCs (79) and on the ability of these APCs to produce IL-12 when 
activated (92).  Unexpectedly, when Nur77
gfp
 mice were infected with S. typhimurium for 
20 hours, iNKT cells did not upregulate GFP expression (Figure 2-5A).  Despite this, 
there was increased expression of CD69 (data not shown) and an increase in the 
percentage of iNKT cells producing IFN (Figure 2-5B). The iNKT cells producing IFN 
did not have a higher mean expression of GFP (Figure 2-5B), unlike what was observed 
for cytokine producing iNKT cells in S. pneumoniae or S. paucimobilis infection (Figure 
2-3B and Figure 2-4B).  To ensure that we did not miss a relevant time point in vivo, we 
evaluated GFP expression at earlier (4 hours) and later (72 hours) times, but did not 
observe a GFP increase (Figure 2-5A). However, at all of the tested time points, there 
was a statistically significant increase in the percentage of iNKT cells producing IFN 
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(Figure 2-5B).  These data suggest that iNKT cells were not receiving stimulation 
through their TCR during S. typhimurium infection, despite being activated to produce 
IFN. 
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Figure 2-5.  S. typhimurium infection induced cytokineproduction, but not GFP 
expression.  Nur77
gfp
 B6 mice were infected with S. typhimurium i.v., and tet
+
 iNKT 
cells were analyzed by flow cytometry directly ex vivo for GFP expression (A) and IFN 
production (B).  The histogram shows uninfected mice (left), 20 h S. typhimurium 
infected (middle) and 3 h GalCer injected (right) animals.  The histogram in (B) shows 
GFP expression of the IFN- iNKT cell population versus the IFN+ iNKT cell population 
from an animal 20 h post infection.  Data show representative dot plots and histogram of 
four independent experiments with four to six animals per time point.  For the percentage 
of IFN+ iNKT cells graph (B), **P = 0.0059, uninfected versus 4 h post infection; ***P 
< 0.0001, uninfected versus 20 h post infection; ***P < 0.0001, uninfected versus 72 h 
post infection (all using unpaired two-tailed t-test). 
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 Given that this result contradicts previous reports (90, 92), we tested if iNKT cells 
could produce IFN in the absence of CD1d expressed by APCs during S. typhimurium 
infection.  This was done by enriching for iNKT cells from the liver and spleen of V14 
TCR transgenic crossed to Nur77
gfp
 transgenic mice, and by adoptively transferring these 
cells into either CD1d-deficient or WT mice.  Host mice were infected with S. 
typhimurium 24 hours after receiving the iNKT cells, and then the transferred iNKT cells 
were analyzed 20 hours after infection.  The transferred iNKT cells did not upregulate 
GFP expression regardless of whether they were recovered from CD1d-deficient or WT 
hosts (Figure 2-6), consistent with the result obtained previously (Figure 2-5).  Despite 
this, iNKT cells from both types of infected hosts produced IFN, and the percentage of 
cytokine producing iNKT cells was not significantly different.  These data suggest that 
iNKT cells were activated independently of CD1d, and thus independently of endogenous 
self-lipid antigen, during S. typhimurium infection. 
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Figure 2-6.  iNKT cell cytokine production was CD1d independent during S. 
typhimurium infection.  iNKT cells were purified from Nur77
gfp 
V14 TCR transgenic 
B6 mice and transferred into either WT hosts (iNKT  WT) or CD1d-/- hosts (iNKT  
CD1d
-/-
).  Mice were then infected with S. typhimurium i.v., and the transferred tet
+
 iNKT 
cells were isolated and analyzed by flow cytometry for intracellular IFN 20 h post 
infection.  Dot plots (left) show representative data of iNKT cells isolated from an 
uninfected WT host (top, left), an uninfected CD1d
-/-
 host (bottom, left), an infected WT 
host (top, right) or infected CD1d
-/-
 host (bottom, right) from two independent 
experiments with three to six animals per group.  *P = 0.0127, uninfected in WT host 
versus 20 h post infection in WT host; *P = 0.0381, uninfected in CD1d
-/-
 host versus 20 
h post infection in CD1d
-/-
 host (all using unpaired two-tailed t-test). 
 
TLR Stimulation Does Not Cause TCR-dependent Activation of iNKT Cells 
The presentation of antigenic endogenous self-lipids by CD1d leading to the 
stimulation of iNKT cells has been proposed to occur as a result of TLR stimulation of 
APCs (89-91).  Specifically, stimulation of TLR4 or TLR9 was suggested to lead to 
increased synthesis and/or presentation of antigenic endogenous self-lipids (79, 89-91).  
In order to test this, we injected Nur77
gfp
 mice with either LPS to stimulate TLR4, or 
CpG oligodeoxynucleotides (ODNs) to stimulate TLR9, and examined iNKT cell 
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activation 4, 24, or 36 hours later.  There was no increase in GFP expression in iNKT 
cells at any time point after TLR activation, despite robust production of IFN and 
elevated expression of CD69 at 4 hours for LPS and 36 hours for CpG (Figure 2-7 and 
data not shown). 
 
Figure 2-7.  iNKT cell cytokine production was CD1d independent during TLR 
stimulation.  Nur77
gfp
 B6 mice were injected with LPS (top panel) or CpG (bottom 
panel) i.v., and tet
+
 iNKT cells were analyzed by flow cytometry 4 or 36 h later, 
respectively, for GFP expression, CD69 expression, and IFN production.  
Representative histograms show GFP expression (left) or CD69 expression (middle) for 
uninjected, LPS or CPG injected, or 2 to 3 h GalCer injected animals from two 
independent experiments with 3 animals per group.  For the percentage of IFN+ iNKT 
cells graph (right, top), **P = 0.0026, uninjected versus 4 h post LPS injection.  For the 
percentage of IFN+ iNKT cells graph (right, bottom), **P = 0.0092, uninjected versus 
36 h post CpG injection (all using unpaired two-tailed t-test). 
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This contradicts the conclusions from a previous report, in which it was found that 
TLR stimulation led to the inhibition of the enzyme -galactosidase A (-Gal A) (89).  
-Gal A was proposed to convert a stimulatory lipid to a non-stimulatory lipid, and thus 
the inhibition of this enzyme would result in the increased presentation of the stimulatory 
lipid for iNKT cell activation (89).  Therefore, we used the Nur77
gfp
 mice with -
Galactosidase A deficient (-Gal A-/-) mice to test this notion.  Initially, we looked at 
GFP expression in Nur77
gfp
:-Gal A-/- mixed bone marrow chimeras to examine iNKT 
cell activation in the steady state in vivo. However, we saw no GFP expression in the 
recovered Nur77
gfp
 iNKT cells (Figure 2-8).  Next, we analyzed a model of acute 
activation of iNKT cells by examining GFP expression after adoptive transfer of iNKT 
cells from Nur77
gfp
 V14 TCR transgenic mice into -Gal A-/- or WT hosts. The Nur77gfp 
V14 TCR transgenic iNKT cells did not have increased GFP expression when 
recovered from -Gal A-/- hosts (Figure 2-9).  Lastly, we performed a direct comparison 
with the reported data, but analyzed GFP expression as a measure of iNKT TCR 
stimulation in addition to the decrease in the GalCer-loaded CD1d-tetramer+ TCR+ 
population used in the previous report as a measure of activation (89).  Similar to the 
prior study, we transferred -Gal A-/- BMDC, GlcCer pulsed -Gal A-/- BMDC, or WT 
BMDC into Nur77
gfp
 recipients.  iNKT cells from animals injected with -Gal A-/- 
BMDC failed to upregulate GFP in comparison to animals injected with WT BMDC, 
while increased GFP expression was seen in iNKT cells from animals injected with 
GlcCer pulsed -Gal A-/- BMDC (Figure 2-10).  
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Figure 2-8.  iNKT cells were not activated in -GalA-/-:Nur77gfp chimeras.  Nur77gfp 
iNKT cells were isolated from -GalA-/-:Nur77gfp mixed bone marrow chimeras and 
analyzed by flow cytometry for GFP expression.  Histogram shows GFP expression for 
Nur77
gfp
 iNKT cells from a WT:Nur77
gfp
 mixed bone marrow chimera and Nur77
gfp 
iNKT cells from -GalA-/-:Nur77gfp mixed bone marrow chimera.  Data shown is 
representative of three independent experiments (WT:Nur77
gfp
 = 3; -GalA-/-:Nur77gfp = 
10).  
 
Figure 2-9. 
  
iNKT were not activated after transfer into -Gal A-/- mice.  iNKT cells 
were enriched from congenic (CD45.1) Nur77
gfp 
V14 TCR transgenic B6 mice and 
transferred into either WT or -GalA-/- recipients.  One day later, the transferred cells 
were recovered with magnetic beads, and tet
+
 cells analyzed by flow cytometry.  
Histograms show representative data of hepatic or splenic iNKT cells isolated from a WT 
recipient or -GalA-/- recipient from one experiment (WT recipient = 3; -GalA-/- 
recipient = 3).  
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Figure 2-10.  -Gal A-/- BMDCs transferred into Nur77gfp mice did not activate 
iNKT cells.  Unpulsed -Gal A-/- BMDC, -Gal A-/- BMDC pulsed with GlcCer, or 
unpulsed WT BMDC were transferred into Nur77
gfp
 mice, and tet
+
 iNKT cells were 
analyzed by flow cytometry 18 h later.  Histogram shows representative GFP expression 
for iNKT cells from mice that received unpulsed WT BMDC, unpulsed -Gal A-/- 
BMDC, or -Gal A-/- BMDC pulsed with GlcCer from two independent experiments 
(WT BMDC = 2, unpulsed -Gal A-/- BMDC = 4, -Gal A-/- BMDC pulsed with 
GlcCer =2). 
 
Activation of iNKT cells can lead to a decreased recovery when using tetramer 
due to TCR internalization (71) and/or activation induced cell death (27, 72).  This 
reduced recovery has been used as a measure of iNKT cell activation in vivo.  However, 
mice from -Gal A-/- BMDC injected groups exhibited variability in the percentage of 
GalCer-loaded CD1d-tetramer+ TCR+ populations recovered (Figure 2-11).  Overall, 
our data are not consistent with the hypothesis that TLR stimulation of APCs leads to the 
presentation of antigenic endogenous self-lipid for the stimulation of iNKT TCRs. 
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Figure 2-11.  Inconsistent TCR internalization in iNKT cells after injection of -Gal 
A
-/-
 BMDC.  Unpulsed -Gal A-/- BMDC, -Gal A-/- BMDC pulsed with GlcCer, or 
WT BMDC were transferred into Nur77
gfp
 mice.  After 18 h, the tet
+
 iNKT cells were 
gated and showed an inconsistent reduction in proportion compared to WT (presumed to 
reflect TCR internalization) when injected with -Gal A-/- BMDC (compare bottom left 
to bottom right). 
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Discussion 
The invariant nature of the iNKT TCR -chain implies that the potential 
repertoire of lipids capable of stimulating iNKT cells must be restricted, which indicates 
that iNKT cells are only activated in a limited context of conditions.  Yet, diverse 
structures have been reported for both the microbial and self-lipids recognized by these 
cells including GSLs, diacylglyerols, phospholipids and cholesterol containing 
compounds (70).  Also, several TCR independent modes of activation of iNKT cells have 
been reported, including the cytokine-mediated activation described above, but also 
stimulation mediated by engagement of activating NK receptors such as NKG2D (66) 
and activation of iNKT cells in the liver by engagement of -adrenergic receptors (155).  
Furthermore, it has been shown that iNKT cells are able to rapidly produce cytokines not 
only in response to bacterial, viral, and fungal infections, but also in response to cancers, 
various inflammatory conditions, and autoimmune diseases (23).  This ability to respond 
in such diverse contexts raises the question as to the importance of TCR-dependent 
pathways in those situations in which iNKT cells play a role in the immune response, and 
also, when the TCR is involved, the relative weight of recognition of self versus foreign 
glycolipids.  
Here we used the Nur77
gfp
 mouse as a sensitive tool to examine the role of iNKT 
cell TCR stimulation during various infections.  We showed that this reporter mouse can 
detect iNKT cell responses to self glycolipid antigens presented by CD1d that have an 
affinity for the iNKT cell TCR of approximately 5 M or weaker, which is nearly 103-
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fold weaker than the affinity for GalCer presented by CD1d.  Using this system, we 
showed that iNKT cells are stimulated through their TCR when infected with pathogens 
known to have antigenic lipids, such as in S. pneumoniae infection or S. paucimobilis 
infection. 
Using infection with MCMV, we showed that iNKT cells became activated in the 
absence of TCR stimulation, consistent with other results showing that cytokines from 
APCs were sufficient to activate a protective response by iNKT cells after this infection 
(88, 151).  Further evidence showing that iNKT cells can undergo TCR-independent 
stimulation was recently reported.  Using a transgenic mouse in which the iNKT TCR 
could be conditionally ablated, it was shown that TCR-negative iNKT cells could still 
mount a response to LPS by producing similar amounts of IFN as compared to iNKT 
cells that retained TCR expression (156).  
More surprising was our findings that iNKT cell TCR stimulation could not be 
detected after either S. typhimurium infection or TLR stimulation of APCs, as these 
observations run counter to a currently popular model (70).  It could be argued that the 
reporter mouse is not sufficiently sensitive, and that while we have tested some of the 
weakest reported TCR agonists, that S. typhimurium induces the presentation of a self-
antigen that has a very low abundance and/or TCR affinity, and therefore cannot give an 
activation signal in the Nur77
gfp
 mice.  We consider this unlikely, however, because when 
transferred to CD1d-deficient hosts, we found that the iNKT cell IFN response to S. 
typhimurium was not impaired.  Regarding the reported TCR-dependence of the iNKT 
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cell response to S. typhimurium, much of the data relied on in vitro studies.  For example, 
in vitro experiments showing that CD1d
-/-
 BMDC were ineffective at inducing IFN 
production by tetramer sorted iNKT cells in response to S. typhimurium are difficult to 
reconcile with our data.  In vivo studies used CD1d-blocking antibodies to demonstrate 
TCR dependent IFN production.  It is possible that antibodies to CD1d could have had a 
direct effect on APCs independently of iNKT cells, which led to a reduction in 
inflammatory cytokine production, and a consequent reduction in IFN production by 
iNKT cells (157).  
Similarly, we did not find that TLR activation of APCs induced a detectable TCR 
signal in iNKT cells, although it was previously reported to increase the synthesis of 
enzymes responsible for the synthesis of stimulatory self-antigens (6, 91, 92, 158).  
Although again, other in vivo experiments showed that iNKT cells with and without a 
TCR produced similar levels of IFN in response to LPS (156).  One possible explanation 
is that a stronger stimulation of the innate immune system achieved in vivo may somehow 
inhibit TCR-dependent activation of iNKT cells.  TLR stimulation was also reported to 
inhibit an enzyme, -Gal A, that would degrade a putative lipid self-antigen (89).  
Regarding the role of -Gal A, using the Nur77gfp reporter mouse, we did not find 
evidence that APCs in mice deficient for this enzyme induced a TCR signal in iNKT cells 
in vivo. In the -Gal A deficient model, the previous data supporting TCR-dependent 
activation of iNKT cells relied upon loss of the GalCer-loaded CD1d-tetramer+ TCR+ 
population and on the increased expression of the surface marker CD69 (89).  In our 
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hands, however, population loss was not a consistent and reliable measure of TCR-
mediated iNKT cell activation, and CD69 expression is not strictly TCR dependent, as it 
is also influenced by inflammatory stimuli.  
In the cases of infection with S. pneumoniae and S. paucimobilis, in which there 
was a detectable TCR signal in the Nur77
gfp
 reporter mouse, the question remains as to 
whether that signal was due to the presence of a foreign antigen or the induction of the 
synthesis of a self-antigen, although these alternatives are not mutually exclusive and 
both types of antigens could be present (6).  The evidence provided here is only 
correlative with the need for a foreign antigen to induce a TCR-mediated signal in the 
infections studied; although if self-antigen were dominant during each of the three 
bacterial infections, it is puzzling that a signal from the reporter mouse could only be 
obtained using bacteria with a foreign antigen.  There is no evidence that the iNKT cells 
from the S. typhimurium infected mice were less activated; in fact, by intracellular 
cytokine staining they were at least as activated as the populations from S. pneumoniae or 
S. paucimobilis infected mice.  It has not been possible to resolve the issue of foreign 
versus self-antigen recognition so far, however, as it has not been feasible to remove 
either the microbial antigen or the self-antigen by genetic deletion, without causing 
unacceptable secondary effects.  For example, S. pneumoniae mutants that cannot 
synthesize the glycosylated diacylglycerol antigen have proved not to be viable (M. 
Kronenberg, unpublished). Regarding the self-antigen, problems include the diversity of 
self-antigens reported, with both GSLs and phospholipids, and secondary effects on the 
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health of the mice and the functioning of the endosomal system in APCs when basic 
components of glycolipid synthesis pathways are eliminated (30, 159).   
Although S. typhimurium infection did not stimulate the iNKT TCR as a result of 
endogenous lipid antigen presentation in our experiments, we are not proposing that this 
pathway for iNKT cell activation is unimportant.  It is known that iNKT cells do receive 
TCR stimulation from endogenous lipid during iNKT cell thymic selection (160, 161).  
For example, in the Nur77
gfp
 mice, intrathymic stage 0 iNKT cell precursors expressed a 
high level of GFP (43).  Furthermore, thymic NKT2 cells from BALB/c mice, which 
produce IL-4 at steady state, showed an increased expression of GFP compared to NKT1 
or NKT17 cells (57).  iNKT TCR stimulation may also be important during homeostasis, 
as a recent report indicated its importance in detection of inhibitory lipids required for the 
regulation of symbiotic microbe homeostasis (162). Additionally, other types of 
infections remain to be tested for iNKT cell TCR stimulation as was done in this report.  
For example, infection with the helminth parasite Schistosoma mansoni, in which iNKT 
cell activation has been shown to be dependent on CD1d after schistosome egg 
encounter, remains one of a number of possible examples of iNKT cell TCR stimulation 
mediated by an antigenic endogenous lipid, as a foreign lipid from S. mansoni has not 
been reported (163). 
In conclusion, we have demonstrated that the Nur77
gfp
 mouse provides a sensitive 
tool for directly measuring iNKT cell TCR stimulation and detecting endogenous and 
foreign lipid agonists even when they vary greatly in potency.  Additionally, our data 
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provided insight into the role of iNKT cell TCR stimulation in iNKT cell activation 
during infections, differentiating between infections that are dependent on TCR 
stimulation and infections that are not.  We showed that TCR-independent activation 
applies to bacterial as well as viral infections, and furthermore, that the ability to detect 
TCR-mediated activation in vivo correlated with the presence of foreign antigen.  This 
approach may be useful to identify those situations in which a self-antigen mediated 
activation of iNKT cells is most relevant, for example, in the context of sterile 
inflammatory conditions such as ischemia reperfusion injury (164). 
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Materials and Methods 
Mice 
Nur77
gfp
 B6 mice were previously described (43). B6 (C57BL/6NCr) and B6.SJL 
(B6-LY.5/Cr) mice were obtained from the National Cancer Institute. CD1d
-/-
 B6 
(B6.129S6-Cd1d1/Cd1d2tm1Spb/J) mice and V14 TCR transgenic B6 (C57BL/6-
Tg(Cd4-TcraDN32D3)1Alben/J) mice were obtained from The Jackson Laboratory.  
Fabry mice deficient for the enzyme -galactosidase A (B6;129-Glatm1Kul/J) were 
obtained from F. Winau (Harvard Medical School).  KN2 mice on the B6 background 
were obtained from M. Mohrs (Trudeau Institute).  KN2 Nur77
gfp
 B6 mice were 
generated by the crossing of KN2 and Nur77
gfp
 mice.  Nur77
gfp
 V14 TCR transgenic B6 
mice were generated by the crossing of V14 TCR transgenic B6 and Nur77gfp B6 mice.  
All animal experimentation was approved by and performed according to the guidelines 
from the Institutional Animal Care and Use Committees at the University of Minnesota 
or at the La Jolla Institute for Allergy & Immunology. 
 
Flow Cytometry, Antibodies, and Intracellular Cytokine Staining 
Single-cell suspensions were prepared from spleens, and hepatic mononuclear 
cells were separated by Percoll gradient centrifugation.  All cells were resuspended in 
staining buffer (PBS with 5% FCS).  Antibodies to surface markers were added, and cells 
were stained on ice for 20 min.  Antibodies used were from eBioscience, BD, or 
BioLegend.  For iNKT cell staining, CD1d monomers loaded with biotinylated PBS57 or 
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unloaded monomers were obtained from the tetramer facility of the US National 
Institutes of Health.  Cells were analyzed on an LSRII (Becton Dickinson) and data was 
processed with FlowJo software (TreeStar).  A dump strategy (CD11b, F4/80, and CD8) 
was used to eliminate non-specific events. 
 For intracellular detection of cytokines, cells were stained for surface markers as 
described above, and then fixed and permeabilized using the Cytofix/CytoPerm buffer 
(BD Biosciences) according to the manufacturer’s protocol.  Anti-IFN (eBioscience) 
was added and the cells were stained on ice for 30 min.  Cells were washed twice and 
then resuspended in staining buffer before analysis on an LSRII. 
 
iNKT Cell Purification 
For iNKT cell adoptive transfer experiments, a single-cell suspension was 
prepared from Nur77
gfp
 V14 TCR transgenic mice spleens, and from hepatic 
mononuclear cells separated by Percoll gradient centrifugation.  This single-cell 
suspension was depleted of B cells and CD8 T cells using anti-CD19 and anti-CD8 
conjugated to magnetic beads, and MACS columns (Miltenyi Biotec), according to 
manufacturer’s protocol.  The percentage of iNKT cells in the enriched fraction was 
~30%, and the equivalent of ~3x10
6
 iNKT cells was adoptively transferred per mouse. 
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In Vivo Infections 
Mouse cytomegalovirus (MCMV-K181) was obtained from C. Benedict (La Jolla 
Institute for Allergy & Immunology).  Mice were infected intra-peritoneally with 1x10
5
 
PFU diluted in 300 ul PBS.  Sphingomonas paucimobilis was obtained from M. 
Kronenberg (La Jolla Institute for Allergy & Immunology).  S. paucimobilis cultured in 
Tryptic Soy Broth (BD) at 37°C was collected at a mid-log phase and washed with PBS. 
Mice were inoculated intravenously with ~1x10
9
 CFU diluted in 200 ul PBS.  
Streptococcus pneumoniae URF918 (clinical isolate, serotype 3) was obtained from M. 
Kronenberg (La Jolla Institute for Allergy & Immunology).  S. pneumoniae cultured in 
Todd-Hewitt broth (BD) at 37°C were collected at a mid-log phase and then washed with 
PBS.  Mice were inoculated intravenously with ~1x10
7
 CFU diluted in 200 ul PBS.  
Salmonella typhimurium (SL1344) was obtained from S. McSorley (University of 
California, Davis).  S. typhimurium cultured in Todd-Hewitt broth (BD) at 37°C was 
collected at a mid-log phase and then washed with PBS.  Mice were inoculated 
intravenously with ~1x10
6
 CFU diluted in 200 ul PBS.  As a control for all infections, 2 
ug of GalCer diluted in 200 ul of PBS was injected intravenously, and spleen and liver 
were harvested two to four hours later.  
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TLR Agonists 
Mice were injected intravenously in a final volume of 200 ul with 50 ug of E. coli 
derived LPS diluted in PBS, or with 10 ug of ODN 1826 diluted in endotoxin free water. 
Spleen and liver were analyzed at the indicated timepoints after injection. 
 
Lipid-pulsed Bone Marrow-derived Dendritic Cells 
Bone marrow cells from femurs of mice were cultured for seven days (5x10
6
 
cells/well) at 37°C in six-well cell culture dishes with complete RPMI medium in the 
presence of recombinant murine GM-CSF (50 ng/ml, PeproTech) and IL-4 (10 ng/ml, 
PeproTech).  On day six, cells were pulsed with either 100 ng–1 ug/ml of GalCer 
(KRN7000, Avanti Polar Lipids), 1 ug/ml OCH (Alexis Biochemicals), 1 ug/ml of 
GlcCer (C24:1 Glucosyl() Ceramide (d18:1/24:1(15Z)), Avanti Polar Lipids), 1ug/ml 
of iGb3 provided by D. Zhou (MD Anderson) or 1 ul/ml solvent (2:1 
methanol:chloroform) for 12–15 hours at 37°C.  BMDCs were intravenously injected into 
Nur77
gfp
 mice (0.5–1.0x106cells/mouse), and endogenous splenic iNKT cells were 
analyzed 16 h later. 
 
Mixed-bone Marrow Chimeras 
Total bone marrow cells were prepared from the femurs of Nur77
gfp
 B6.SJL 
(CD45.1
+
CD45.1
+
), B6 (CD45.2
+
CD45.2
+
), or Fabry B6 (CD45.2
+
CD45.2
+
) donor mice, 
and samples were depleted of mature T cells with anti-Thy1.2 (30-H12; Biolegend) and 
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complement.  Recipient mice (CD45.2
+
 CD45.1
+
) were lethally irradiated (1,000 rads) 
and received 1x10
7
 adult bone marrow cells.  Chimeras were analyzed eight weeks after 
transplantation. 
 
Statistical Analysis 
Prism software (GraphPad) was used for statistical analysis.  Unpaired two-tailed 
t-tests were used for data analysis. 
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Chapter 3: Deriving iNKT Cells from Hematopoetic 
Progenitor Cells In Vitro 
  66 
CD1d-restricted invariant Natural Killer T cells (iNKT cells) play a vital role in 
determining the kinetics, extent, and characteristics of an immunological response.  iNKT 
cells influence an immune response by producing large amounts of the cytokines IFN, 
IL-4, and IL-17, from three major subsets: NKT1, NKT2, and NKT17.  iNKT cells have 
been shown to be involved in cancer, autoimmune disease, asthma, and infection.  
Therefore, there is great potential for the use of iNKT cell based therapeutics to 
beneficially influence the immune response.  In this study, we sought to develop an in 
vitro system to generate iNKT cells, and to define the conditions that result in the iNKT 
cell subset differentiation into NKT1, NKT2, and NKT17.  We used the bone marrow 
stromal cell line OP9 engineered to ectopically express the Notch ligand, Delta-like-1 
(DL1), to induce fetal liver hematopoietic progenitor cells to become iNKT cells.  We 
found that it was necessary to use a source of V14 T cell receptor (TCR) transgenic 
(Tg) fetal liver hematopoietic progenitor cells in order to detect a 
CD1d/galactosylceramide tetramer+ (CD1d/GalCer tet+) TCR+ population.  These 
CD1d/GalCer tet+ TCR+ cells expressed PLZF and Tbet similarly to the iNKT cell 
subset NKT1; however, there was a temporal component to this expression: 
CD1d/GalCer tet+ TCR+ cells were initially detected, followed by the detection of 
PLZF
+
 CD1d/GalCer tet+ TCR+ cells, and then lastly, by the detection of PLZFlo Tbet+ 
CD1d/GalCer tet+ TCR+ cells.  Interestingly, the addition of IL-15 enhanced the 
percentage of CD1d/GalCer tet+ TCR+ cells expressing Tbet.  The function of these 
cells was assessed by adoptive transfer and stimulation in vivo, where upon these OP9-
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DL1 derived CD1d/GalCer tet+ TCR+ cells rapidly produced IFN.  Overall, this study 
showed that the V14 TCR Tg fetal liver OP9-DL1 culture system successfully gave rise 
to CD1d/GalCer tet+ TCR+ NKT1-like cells that expressed the important iNKT cell 
transcription factors PLZF and Tbet, as well as rapidly produced IFN after stimulation.  
These findings indicate that this culture system can be used as a powerful tool for the 
further analysis of iNKT cell development, and potentially for iNKT cell-based therapies. 
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Introduction 
 CD1d-restricted Natural Killer T cells (iNKT cells) are a distinct lineage of  T 
lymphocytes with a semi-invariant T cell receptor (TCR) (19).  In mice, this iNKT TCR 
is composed of the TCR -chain variable region 14 (V14) and the -chain joining 
region 18 (J18) paired with a restricted subset of TCR- chains (V8.2, 7 or 2) (19).  
Upon stimulation, iNKT cells are able to rapidly produce cytokines, such as IFN, IL-4, 
and IL-17 (48).  This rapid cytokine production contributes to the activation of other cell 
types during the immune response, which has been shown to influence a variety of 
diseases, including cancer (119), autoimmunity (140, 141), and pathogenic infection 
(127). 
More specifically in the context of cancer, iNKT cells have been shown to boost 
the anti-tumor response (116).  In a B16 melanoma model, iNKT cells were shown to be 
required for IL-12 mediated tumor rejection (119).  In another study, IFN produced by 
iNKT cells activated by the strong agonist galactosylceramide (GalCer) was shown to 
be protective against B16 melanoma metastases (120).  Additionally, activated iNKT 
cells were shown to be directly involved in the antitumor response by contributing to 
antitumor cytotoxicity (121).  However, it has also been shown that the frequency of 
iNKT cells in cancer patients were significantly lower than in healthy volunteers (122, 
124, 126), and that this decreased iNKT cell number predicted poor clinical outcomes 
(125).  Furthermore, the iNKT cells from these patients exhibited decreased proliferation 
and cytokine production after ex vivo stimulation (126).  Together, these studies indicate 
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an iNKT cell-based therapeutic could be a powerful new cancer treatment; however, for 
such a treatment to be effective, a patient will need to have a sufficient number of 
functional iNKT cells.  Therefore, in this study we sought to derive a source of 
exogenous iNKT cells.  
Previous work has shown that the stromal cell line, OP9, can support the 
differentiation of hematopoietic progenitor cells (HPCs) into multiple lineages, such as B 
cells (129, 130).  However, only when OP9 cells were retrovirally transduced to express 
the Notch ligand Delta-like-1 (DL1) were these cells able to support T cell development 
(131).  The expression of DL1 allowed for activation of Notch signaling, which is 
essential for determining whether lymphocyte progenitors adopt a T cell fate over a B cell 
fate (131).  With the ectopic expression of DL1, OP9-DL1 cells co-cultured with HPCs 
were able to differentiate into the T cell lineage specific Double Negative (DN) stages 
and then into the CD4
+
 CD8
+
 Double Positive (DP) stage similarly to the T cell 
development that occurs in the thymus (131).  However, these cultures do not yield fully 
mature, functional T cells in the absence of thymic epithelial cells, as they are unable to 
undergo normal positive selection.  
Importantly, iNKT cells follow the same progression through T cell development 
until the DP stage (29, 42, 137).  At the DP stage, rare DP thymocytes expressing the 
iNKT TCR are positively selected by a self-lipid presented by CD1d expressed on other 
DP thymocytes (29, 42, 43).  Homophilic interactions between SLAM family members 
expressed on the surface of DP thymocytes are also required to initiate essential signals 
  70 
for iNKT cell development (42, 44-46).  During or immediately after this selection event, 
one of the main transcriptional regulators of iNKT cell development, PLZF 
(promyelocytic leukemia zinc finger, encoded by Zbtb16), is expressed (50, 51).  PLZF 
has been shown to direct the innate-like effector differentiation of iNKT cells during 
thymic development, and is later important for appropriate cellular trafficking and 
functionality (50, 51).  After PLZF expression is initiated, iNKT cells undergo further 
differentiation into three main subsets, NKT1, NKT2 and NKT17 (57).  These three 
subsets are distinguished by their transcription factor profiles, and can be separated into 
the three populations based on their expression of PLZF, RORt and Tbet: NKT1 cells 
are PLZF
lo
 Tbet
+
, NKT2 cells are PLZF
hi
 Tbet
-
 RORt-, and NKT17 cells are PLZFint 
RORt+ (57).  This subset differentiation is important as it dictates the main cytokine 
produced by the cells after stimulation, which influences the subsequent immune 
response.  NKT1 cells produce IFN NKT2 cells produce IL-4, and NKT17 produce IL-
17 (56, 57).  
  Since iNKT cells develop from DP cells, the OP9-DL1 culture system can be used 
to derive iNKT cells.  Three previous studies have examined this possibility using HPCs, 
iNKT cell derived embryonic stem cell (ESC) lines, or iNKT cell induced pluripotent 
stem cells (iPSCs) cultured with OP9-DL1 to derive iNKT cells in vitro (47, 138, 139).  
However, the iNKT cells derived from HPCs cultured with OP9-DL1 were very transient, 
making this finding debatable (47).  Additionally, since iNKT cells are a heterogenous 
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population, determination of what subsets developed is very important for future 
therapeutic use, which was not done in any of the previous studies. 
Here, we showed that using HPCs with a fixed V14-J18 TCR was necessary to 
detect a CD1d/galactosylceramide tetramer+ (CD1d/GalCer tet+) TCR+ population.  
We found that CD1d/Gal tet+ TCR+ population was undetectable using wild type 
HPCs, which was presumably due to the low frequency of generating the appropriate 
V14/J18 recombination event.  We then examined the transcription factor profile of 
the derived CD1d/Gal tet+ TCR+ cells to determine which iNKT subsets were present, 
and tested these cells for cytokine production after TCR stimulation in vivo. 
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Results 
Induction of T Cell Differentiation in V14 TCR Tg Fetal Liver Hematopoietic 
Progenitor Cells Using the OP9-DL1 Culture System 
 This study sought to demonstrate an in vitro approach to derive iNKT cells from 
hematopoietic progenitor cells (HPCs).  Previous work showed that the bone marrow 
stromal cell line, OP9, can support the differentiation of HPCs into multiple lineages, 
such as B cells (129, 130), and that when these OP9 cells were retrovirally transduced to 
express the Notch ligand DL1, this cell line supported T cell development (131).  Since 
iNKT cells follow the same developmental pathway as conventional T cells until the DP 
stage (29, 42, 137), we used the OP9-DL1 culture system to derive iNKT cells from 
HPCs. 
At the DP stage of T cell development, iNKT cells are selected from the DP pool 
of thymocytes based upon the interaction between their invariant TCR and the selecting 
lipid ligand presented by other DP thymocytes (29, 137).  However, the frequency of DP 
thymocytes that express the required TCR is very small in the wild type (WT) animals.  
Therefore, we decided to use V14 TCR Transgenic (V14 TCR Tg) animals as the 
source of HPCs (V14 HPCs).  Since V14 TCR Tg mice express a fixed V14-J18 
TCR, the percentage of DP thymocytes that express the invariant TCR required for iNKT 
cell selection is greatly increased (165).  However, since we are using a TCR transgenic 
source of HPCs, we first wanted to ensure that this TCR expression was not altering the 
ability of the V14 HPCs to develop normally. 
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We first tested the ability of V14 HPCs to undergo B cell development.  To do 
this, HPCs were isolated from the fetal livers of day 15 V14 TCR Tg embryos.  HPCs 
were enriched for CD24
lo
 Lin
-
 cells by CD24 complement depletion and then placed into 
culture with OP9 cells.  Cells were harvested at day 7, 12, and 17, and were analyzed by 
flow cytometry for B cell development using CD19.  By day 12 there was a large 
population of CD19
+
 cells, which was still present at day 17, indicating that V14 HPCs 
had differentiated into the B cell lineage (Figure 3-1A).  These cells were also analyzed 
for markers of T cell development. During T cell development, T cell progenitors go 
through four Double Negative (DN) stages before reaching the CD8
+
 CD4
+
 Double 
Positive (DP) stage.  The progression through the DN stages is marked by differential 
expression of the markers CD25 and CD44, in which DN stage 1 cells are CD44
+
 CD25
-
, 
DN stage 2 cells are CD44
+
 CD25
+
, DN stage 3 cells are CD44
lo
 CD25
+
, and DN stage 4 
cells are CD44
-
 CD25
-
.  After DN stage 4, cells will then progress to the DP stage.  The 
cells derived from the V14 HPCs did not express the markers for the four DN stages or 
the DP stage, indicating they did not undergo T cell lineage commitment under these 
conditions (Figure 3-1A).  Therefore, expression of the V14-J18 fixed TCR did not 
interfere with the ability of HPCs to undergo B cell development nor did it predispose 
these HPCs to undergo T cell development in the absence of Notch signaling. 
Next, we tested whether the V14 HPCs would undergo T cell commitment 
similarly to HPCs from WT animals.  As done in the OP9 cell co-culture, HPCs were 
isolated from fetal livers of day 15 WT embryos or V14 TCR Tg embryos.  After 
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enriching for HPCs, these cells were placed in parallel cultures with OP9-DL1 cells.  
Cells were then harvested at day 7, 12, 17, 22, 26, 33, and 37, and were again examined 
by flow cytometry for B cell development using CD19, and for T cell development using 
CD25, CD44, CD4, and CD8.  Cells derived from both WT HPCs and V14 HPCs did 
not express CD19, indicating that B cell development was equally inhibited in both 
cultures at all time points (Figure 3-1B and data not shown).  Additionally, cells derived 
from both cultures underwent similar T cell lineage commitment.  These cells followed a 
similar progression through the four DN stages as shown by their CD25 and CD44 
expression, as well as a similar emergence of a DP population at day 12 that was 
maintained at all subsequent time points (Figure 3-1B).  These results indicate that cells 
derived from V14 HPCs underwent similar Notch-dependent T cell commitment as 
cells derived from WT HPCs. 
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Figure 3-1.  V14 TCR Tg hematopoietic progenitors underwent Notch-dependent 
T cell commitment similar to WT hematopoietic progenitor cells.  Flow cytometric 
analysis for the B cell marker (CD19) or T cell development markers (CD25, CD44, 
CD4, and CD8) from V14 HPCs cultured with OP9 cells (A), V14 HPCs cultured with 
OP9-DL1 cells (B, right), or WT HPCs cultured with OP9-DL1 cells (B, left).  Cells were 
harvested at time points indicated.  Numbers in quadrants for CD44 and CD25 expression 
indicate DN stages.  Contour plots in (A) are representative of two to four co-cultures at 
each time point from three independent experiments.  Contour plots in (B, right) are 
representative of two to four co-cultures at each time point from five independent 
experiments.  Contour plots in (B, left) are representative of four co-cultures at each time 
point. 
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V14 TCR Tg Fetal Liver Hematopoietic Progenitor Cells Give Rise to 
CD1d/GalCer Tetramer Binding Cells Using the OP9-DL1 Culture System 
 iNKT cells follow the same developmental pathway as conventional T cells until 
the DP stage (29, 137).  At the DP stage, DP thymocytes that express the iNKT cell TCR 
are positively selected by interactions with other DP thymocytes to become iNKT cells 
(42).  As shown above, V14 HPCs cultured with OP9-DL1 gave rise to a large 
population of DP cells (Figure 3-1B).  Therefore, we next tested the cultures for the 
presence of a CD1d/GalCer tet+ TCR+ population.  The cultures were examined at day 
7, 12, 17, 22, 26, 33, and 37 (Figure 3-2 and data not shown).  At day 7, no 
CD1d/GalCer tet+ TCR+ population was present.  However, by day 12 and at every 
time point after, there was a stable population of CD1d/GalCer tet+ TCR+ cells.  The 
emergence of CD1d/GalCer tet+ TCR+ cells coincided with the appearance of DPs in 
culture (Figure 3-1B), indicating that these cells are most likely arising from the DP 
population as would be expected based on normal iNKT cell development.  Interestingly, 
in a parallel culture using WT HPCs, no population of CD1d/GalCer tet+ TCR+ cells 
was detected (Figure 3-2B).  Thus using V14 HPCs was necessary to increase the 
frequency of DPs expressing the required iNKT TCR in order to obtain a detectable 
population of CD1d/GalCer tet+ TCR+ population. 
 We additionally performed controls to ensure that the population in the culture 
was a CD1d/GalCer tetramer specific population.  Both control V14 TCR Tg 
thymocytes and cells harvested from a day 22 V14 co-culture were stained with either a 
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CD1d/GalCer loaded tetramer or a CD1d/unloaded tetramer (Figure 3-2A).  The 
CD1d/GalCer loaded tetramer, which will bind to the iNKT TCR, should accurately 
stain the population of cells expressing the specific TCR expressed by iNKT cells (27).  
In contrast, the CD1d/unloaded tetramer, which will not be able to bind the iNKT TCR, 
should not detect any tetramer
+
 population.  As expected, the cells from the V14 TCR 
Tg thymus stained with the CD1d/GalCer tetramer had a robust population of tetramer+ 
cells, which was not seen when stained with the CD1d/GalCer unloaded tetramer.  
Similarly, the day 22 V14 co-culture’s cells stained with the CD1d/GalCer tetramer 
had a robust population of tetramer
+ 
cells, and the cells stained with the CD1d/GalCer 
unloaded tetramer did not.  Therefore, the CD1d/GalCer tetramer is accurately staining 
cells harvested from the OP9-DL1 co-culture system that express the iNKT TCR, 
confirming that CD1d/GalCer tet+ cells can be derived from V14 HPCs using this 
culture system. 
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Figure 3-2.  A transgenic V14-J18 TCR was necessary to detect CD1d/GalCer 
tetramer binding cells in the OP9-DL1 culture system.  Thymocytes from a V14 
TCR Tg thymus (A, left column) or cells from a day 22 V14 co-culture (A, right 
column) were stained with either CD1d/GalCer loaded tetramer (A, top row) or 
CD1d/unloaded tetramer (A, bottom row).  WT co-culture cells (B, top row) or V14 co-
culture cells (B, bottom row) were analyzed by flow cytometry for a CD1d/GalCer tet+ 
TCR+ population at the indicated time points.  Contour plots in (A) are representative of 
three experiments or four co-cultures. Contour plots in (B) are representative of two to 
four co-cultures from one (WT) or five (V14) independent experiments. 
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CD1d/GalCer Tet+ TCR+ Cells Express the Transcription Factor PLZF 
 Although a population of CD1d/GalCer tet+ TCR+ cells are present in the OP9-
DL1 culture system by day 12, the ability to bind CD1d/GalCer tetramer does not alone 
mean that these cells are iNKT cells.  The ability to bind tetramer merely indicates that 
the cells have the correct TCR that will strongly interact with the tetramer.  This is 
exemplified in V14 TCR Tg CD1d-/- mice.  Such mice have a detectable population of 
CD1d/GalCer tet+ TCR+ cells (Figure 3-3A); however, these animals lacked CD1d, 
which is required for iNKT selection.  These CD1d/GalCer tet+ TCR+ cells exhibited a 
lack of PLZF expression, indicating they were not selected and therefore not iNKT cells 
(Figure 3-3A) (50, 51).  Thus we next examined PLZF expression in the CD1d/GalCer 
tet
+
 TCR+ population from co-cultures at day 12, 17, 22, 26, 33, and 37 (Figure 3-3B 
and data not shown).  At day 12, the CD1d/GalCer tet+ TCR+ population did not 
express PLZF, indicating that these cells had not yet been positively selected by other DP 
cells to initiate PLZF expression.  However, by day 17, there is a small percentage of 
CD1d/GalCer tet+ TCR+ population that expressed PLZF, which continued to increase 
at subsequent time points.  By day 26, the proportion of PLZF
+
 CD1d/GalCer tet+ 
TCR+ cells had become significantly increased compared with day 12 (Figure 3-3C).  
These results show that PLZF can be induced in the CD1d/GalCer tet+ TCR+ 
population using the OP9-DL1 culture system, indicating these cells were selected and 
initiated the iNKT cell developmental program. 
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Figure 3-3.  PLZF was induced in CD1d/GalCer tet+ TCR+ cells.  Thymocytes 
from a V14 TCR Tg thymus or V14 TCR Tg CD1d-/- thymus were examined by flow 
cytometry for CD1d/GalCer tet+ TCR+ cells (A, top).  The CD1d/GalCer tet+ TCR+ 
population were then analyzed for PLZF expression (A, bottom).  Cells from V14 co-
culture were also examined by flow cytometry for CD1d/GalCer tet+ TCR+ cells at the 
times indicated (B, top).  These CD1d/GalCer tet+ TCR+ populations were then 
analyzed for PLZF expression at the times indicated (B, bottom).  PLZF expression of the 
CD1d/GalCer tet+ TCR+ population was significantly increased in cells analyzed on 
day 26 versus day 12 of the co-culture.  Contour plots are representative of two to four 
co-cultures from one to three independent experiments.  In the graph, each dot indicates 
one co-culture (day 12 = 8; day 26 = 8).  ***P < 0.001, percentage of PLZF
+
 
CD1d/GalCer tet+ TCR+ cells from day 12 versus day 26 (unpaired two-tailed t-test).  
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CD1d/GalCer Tet+ TCR+ Cells Express the Transcription Factor Tbet, Which Is 
Enhanced by the Addition of IL-15 
The percentage of PLZF
+
 CD1d/GalCer tet+ TCR+ cells continued to increase 
until day 37, where there was an observable drop in the proportion (Figure 3-4A).  One 
possible explanation for this drop is that the CD1d/GalCer tet+ TCR+ cells are 
differentiating into the NKT1 subset.  NKT1 cells are characterized by lower PLZF 
(PLZF
lo
) expression accompanied by the expression of the transcription factor Tbet (57).  
Therefore, we examined Tbet expression in the CD1d/GalCer tet+ TCR+ population.  
Tbet expression was not increased until after PLZF expression was initiated (Figure 
3-4A).  Interestingly, the largest increase in the percentage of CD1d/GalCer tet+ TCR+ 
cells expressing Tbet coincided with the observed late decrease in the percentage of 
CD1d/GalCer tet+ TCR+ cells expressing PLZF, indicating that the Tbet+ cells were 
mimicking the PLZF
lo
 Tbet
+
 transcription factor profile of NKT1 cells.  
 However, the percentage of Tbet expressing CD1d/GalCer tet+ TCR+ cells was 
low.  Since Tbet expression is important for iNKT cell IFN production, we sought to 
determine if we could increase the percentage of CD1d/GalCer tet+ TCR+ cells 
expressing Tbet, and thus skew more cells toward the NKT1 lineage.  It was previously 
shown that IL-15 is important for iNKT cell survival and is involved in Tbet regulation in 
cells expressing the NKT1 cell phenotype (60, 61).  Therefore, we added IL-15 to co-
cultures at day 7 or day 17.  This addition of IL-15 greatly increased the percentage of 
CD1d/GalCer tet+ TCR+ cells expressing the PLZFlo Tbet+ transcription factor profile 
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(Figure 3-4B).  More specifically, at day 33, co-cultures with IL-15 showed a significant 
increase in the percentage of CD1d/GalCer tet+ TCR+ expressing Tbet as compared to 
parallel co-cultures without IL-15 (Figure 3-4C).  Together, this data showed that some 
CD1d/GalCer tet+ TCR+ cells from the OP9-DL1 culture system expressed Tbet with a 
similar PLZF
lo
 Tbet
+
 transcription factor profile as NKT1 cells, and the proportion was 
enhanced by the addition of IL-15. 
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Figure 3-4.  IL-15 enhanced the percentage of Tbet
+
 CD1d/GalCer tet+ cells in the 
OP9-DL1 culture system.  The average percentage of CD1d/GalCer tet+ TCR+ cells 
of total cells, PLZF
+
 cells of CD1d/GalCer tet+ TCR+ cells, or Tbet+ cells of 
CD1d/GalCer tet+ TCR+ were analyzed from V14 co-cultures at the indicated time 
points (A).  CD1d/GalCer tet+ TCRb+ cells from a V14 TCR Tg thymus, day 33 V14 
co-culture, or day 33 V14 co-culture with added IL-15 were analyzed for PLZF and 
Tbet expression (B).  The percentage of CD1d/GalCer tet+ TCR+ Tbet+ cells from day 
33 V14 co-cultures with added IL-15 was significantly higher than the percentage of 
Tbet
+
 CD1d/GalCer tet+ TCR+ cells from day 33 V14 cocultures without added IL-
15 (C).  The graph in (A) shows the average of each positive population of two to four 
co-cultures from four independent experiments.  The contour plots show representative 
data of eight co-cultures from two independent experiments.  For the graph in (C), each 
dot represents one co-culture from two independent experiments (-IL15 = 8; +IL15 = 8). 
***P = 0.0002, percentage of Tbet
+
 CD1d/GalCer tet+ TCR+ cells without added IL-
15 versus percentage of Tbet
+
 CD1d/GalCer tet+ TCR+ cells with added IL-15 (paired 
two-tailed t-test). 
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CD1d/GalCer Tet+ TCR+Cells Produce IFN After Stimulation with GalCer 
 Since some of the CD1d/GalCer tet+ TCR+ population resembled the PLZFlo 
Tbet
+
 transcription factor profile of the NKT1 subset, we next tested if these cells were 
also functionally similar to NKT1 cells in vivo (Figure 3-5A).  When stimulated with the 
strong iNKT cell agonist lipid GalCer, NKT1 cells rapidly produce IFN (57).  In order 
to test this, cells from day 37 of V14 OP9-DL1 co-cultures (Figure 3-5B) were injected 
i.v. into congenically different mice.  After 12 hours the mice were injected i.v. with 
GalCer.  Three hours later, the spleen and liver were harvested, and the injected cells 
were recovered based on their congenic marker expression using Magnetic Assisted Cell 
Sorting (MACS) before analysis by flow cytometry.  A population of injected cells was 
recovered in the both the liver and spleen, indicating that the cells from the OP9-DL1 co-
culture were capable of homing to these tissues (Figure 3-5C).  A population of these 
cells was also found in the thymus (data not shown).  Only the cells from mice stimulated 
with GalCer produced IFN (Figure 3-5C).  Together, these data indicate that the 
CD1d/GalCer tet+ TCR+ cells derived from V14 HPCs using the OP9-DL1 co-
culture system functionally mimic NKT1 cells by producing IFN upon stimulation. 
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Figure 3-5.  CD1d/GalCer tet+ TCR+ cells produced IFN upon stimulation with 
GalCer in vivo.  Schematic of V14 HPC co-culture with OP9-DL1, transfer to mice, 
and in vivo stimulation with GalCer (A).  The PLZF and Tbet expression of the day 37 
cells transferred into mice (B).  The percentage of transferred CD1d/GalCer tet+ TCR+ 
cells expressing IFN harvested from the spleen (C, top row) or liver (C, bottom row) 
from either unstimulated mice (C, left column) or stimulated mice (C, right column).  
Contour plots are representative of two mice from one experiment. 
  86 
Discussion 
 iNKT cells have been shown to influence a variety of diseases, such as cancer, 
autoimmune disease, and various infectious diseases.  This influence is thought to be due 
to their ability to rapidly produce cyotkines, which can be artificially initiated by the 
strong agonist, GalCer (26). For example, in some cancers, it has been shown that IFN 
produced by GalCer activated iNKT cells aids in the antitumor response by activating 
other immune cells and by direct tumor cytotoxicity (120, 121).  However, clinical trials 
using GalCer to boost the antitumor response have not proven particularly effective 
(122, 123).  This may be due to decreased numbers of iNKT cells observed in cancer 
patients (124, 125).  Furthermore, the iNKT cells that remain have decreased cytokine 
production and proliferation after ex vivo stimulation (126).  The reason for the decrease 
in iNKT cell number and function is not known, but could be a result of autoantigen 
presented by tumors causing activation induced cell death and/or anergy, or suppression 
of iNKT cells by Tregs (127, 128).  Therefore, for any iNKT cell based therapy to be 
effective, the number of functional iNKT cells needs to be supplemented. One way this 
can be achieved is by cell therapy with iNKT cells.  In this study, we used the OP9-DL1 
culture system to derive iNKT cells from HPCs.  We showed that HPCs gave rise to 
CD1d/GalCer tet+ TCR+ cells that expressed PLZF, an important transcription factor 
required for normal iNKT cell development.  A portion of these cells also expressed Tbet, 
an important transcription factor for the development of NKT1 cells (57), and similarly to 
NKT1 cells, these cells produced IFN after stimulation with GalCer. 
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 Interestingly, we found that the days when PLZF or Tbet were expressed varied 
between independent co-cultures.  In some co-cultures, PLZF expression was initiated by 
day 17, whereas in other co-cultures, this expression did not begin until day 22 or day 26.  
This same variability was seen with Tbet expression, in which there was one co-culture 
where Tbet expression was initiated by day 26 whereas in other co-cultures, the same 
level of Tbet expression was not seen until day 33 or day 37.  In contrast, in parallel co-
cultures within the same experiment, PLZF and Tbet expression initiation occurred on the 
same days.  We hypothesize that this variability between independent cultures was due to 
differences in the plated cell density, as the plated cell density varied between 
independent experiments but not within experiments, indicating that interactions between 
cells is important not only for the initial selection of iNKT cells, but may also be 
important for later transcription factor initiation. 
 Importantly, we found that it was necessary to use HPCs with a fixed V14-J18 
TCR to detect the CD1d/GalCer tet+ TCR+ population.  We hypothesize that this is 
due to the low frequency of WT DP cells expressing the semi-invariant iNKT TCR. 
However, this is in opposition to a previous report which showed that HPCs cultured with 
OP9-DL1 gave rise to a population of iNKT cells, albeit very transiently (47).  This 
iNKT cell population was only seen on day 17 of co-culture, and was not observed before 
or after this time point.  Although it is difficult to reconcile this result with our data, as 
we saw no CD1d/GalCer tet+ TCR+ population in WT cultures at any time point 
examined (day 7, 12, 17, 22, 26, 33, and 37; Figure 3-2 and data not shown), it is possible 
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that we missed the small window in which this iNKT cell population appeared.  
However, others have tried to recapitulate this data, but, to our knowledge, no one has 
done so successfully (T. Malleveay, personal communication). 
 Our data showed that NKT1-like cells can be derived from these co-cultures, 
indicating this system can potentially be used to derive iNKT cells for therapeutic uses 
where IFN is important.  However, as mentioned above, we found that it was necessary 
to use HPCs from V14 TCR Tg mice.  The need for HPCs that have increased 
expression of the invariant iNKT TCR is a potential barrier to using this co-culture 
strategy for therapeutic applications in humans, as the frequency of the invariant iNKT 
cell TCR expression in humans is similarly as low as in wild type mice.  One possible 
solution to this would be to retrovirally transduce HPCs to express the iNKT TCR.  Two 
recent reports provide two alternative strategies that also addressed this problem. In one 
study, nuclear transfer from mature iNKT cells (with a V14-J18 rearranged TCR) 
were used to create embryonic stem cell (ESC) lines, which were then cultured with OP9-
DL1 cells (139).  DNA extracted from these ESC lines were positive for the iNKT TCR, 
and therefore when cultured with OP9-DL1 cells, successfully gave rise to iNKT cells.  
As there are potential ethical issues surrounding the use of embryos to create these iNKT-
ESC lines, the same group showed splenic iNKT cells could be reprogrammed into 
induced pluripotent stem cells (iPSCs) (138).  These iPSCs were then cultured with OP9-
DL1 cells, and differentiated into iNKT cells.  In vitro stimulation with GalCer showed 
these derived iNKT cells could produce IFN; however, no in vivo tests were performed. 
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Although these two previous reports showed successful derivation of iNKT cells 
from ESCs or iPSCs, unlike our work, they did not examine transcription factors to 
identify which subsets were being produced.  This distinction is important, as PLZF is 
required for iNKT cell differentiation, and other transcription factors (Tbet, RORt, and 
GATA3) distinguish the iNKT subsets, which dictates the cytokine produced upon 
stimulation and affects the subsequent immune response (57).  Interestingly, Watarai et 
al. observed that stimulated iPSC-derived iNKT cells from an earlier time point (day 20) 
were not functional (as compared to day 25) (138).  They reasoned that these stimulated 
iNKT cells were not able to produce cytokine because they were too immature, but 
provided no further explanation.  We hypothesize that this observation was due to lack of 
PLZF and/or Tbet expression in these cells.  Tbet controls expression of IFN (166), and 
thus iNKT cells that express Tbet produce IFN (57).  Additionally, we observed a 
kinetic pattern of CD1d/GalCer tet+ TCR+ cells, PLZF expression, and then Tbet 
expression, sequentially.  This pattern of expression comports with the lack of IFN 
production seen by the immature iNKT cells in contrast to the later iNKT cells that were 
able to produce IFN.  Also, in our in vivo functional experiment, not all the injected 
V14 day 37 cells produced IFN upon stimulation.  Since not all the injected cells 
expressed Tbet, we hypothesize that the IFN producing cells were only the cells that 
expressed Tbet.  This indicates that Tbet expression, and more generally identification by 
transcription factor expression, is important before the therapeutic use of these derived 
iNKT cells.  
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In conclusion, we have demonstrated that HPCs co-cultured with OP9-DL1 cells 
gave rise to NKT1-like cells.  These cells expressed both PLZF and Tbet, and the 
percentage of cells expressing Tbet was enhanced by the addition of IL-15.  Notably, the 
frequency of iNKT TCR expressing cells needed to be increased above WT levels to 
detect a CD1d/GalCer tet+ TCR+ population.  Together, these data indicate that this 
culture system can be used as a new tool to address many difficult questions about iNKT 
cell development, such as what factors and/or cytokines are important in the 
differentiation of iNKT cell subsets.  This work also advances previous work toward the 
achievement of iNKT cell-based therapies that harness the different cytokine-producing 
abilities of each iNKT cell subset for personalized disease treatment. 
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Methods and Materials 
Mice 
B6 (C57BL/6NCr) and B6.SJL (B6-LY.5/Cr) mice were obtained from the 
National Cancer Institute.  CD1d
-/-
 B6 (B6.129S6-Cd1d1/Cd1d2tm1Spb/J) mice and 
V14 TCR Tg B6 (C57BL/6-Tg(Cd4-TcraDN32D3)1Alben/J) mice were obtained from 
The Jackson Laboratory.  V14 TCR Tg CD1d-/- B6 mice were generated by the crossing 
of CD1d
-/-
 B6 and V14 TCR Tg B6 mice.  Timed-pregnant B6 or V14 TCR Tg B6 
were used as the source of day 15 embryos for harvesting fetal liver.  All animal 
experimentation was approved by and performed according to the guidelines from the 
Institutional Animal Care and Use Committees at the University of Minnesota. 
 
Cell Lines 
The OP9-GFP and O9-DL1 cell lines were obtained from D. Kaufman (University 
of Minnesota).  OP9-GFP cells and OP9-DL1 cells were cultured as monolayers in OP9 
media (MEM supplemented with 20% FCS, 100 IU/ml penicillin, 100 ug/ml 
streptomycin, 20 ug/ml gentamicin, and 2.2g/liter of sodium bicarbonate). 
 
OP9 and OP9-DL1 Co-cultures 
 Hematopoietic progenitor cell co-culture with OP9-GFP cells or OP9-DL1 cells 
was setup following a previously described protocol (167).  Briefly, day 15 embryos were 
obtained from timed-pregnant females, and fetal livers were extracted.  PCR was used to 
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identify V14 TCR Tg genotype of each embryo before pooling fetal livers.  
Hematopoietic progenitor cells (HPCs) were then isolated by enrichment for CD24
lo
/Lin
-
 
cells by anti-CD24 antibody/complement-mediated depletion (Carlyle 1998).  HPCs were 
then seeded at 6 x 10
5
 cells/plate into 10 cm tissue culture dishes containing a confluent 
monolayer of OP9-GFP cells or OP9-DL1 cells.  All co-cultures were performed in the 
presence of 1 ng/ml IL-7 (PeproTech) and 5 ng/ml Flt3L (R&D Systems).  
At days 7, 12, 17, 22, 26, 33 and 37, non-adherent cells were collected by 
vigorous pipetting, and filtered through a 70 m filter.  The adherent cells were treated 
with 0.25% trypsin (Gibco) for 5 min before adding OP9 media and transferring the 
resulting single-cell suspension to a new 10 cm dish for 45 min.  The non-adherent cells 
were filtered through a 70 m filter and added to the previously collected non-adherent 
cells.  These cells were then split either 1:2 or 1:4 and replated to a 10 cm dish containing 
a fresh monolayer of OP9-GFP cells or OP9-DL1 cells and fresh OP9 media with new 
IL-7 (1 ng/ml, Peprotech) and Flt3L (5 ng/ml, R&D Systems).  Alternatively, some 
cultures also received 10 ng/ml IL-15 (eBioscience) starting at day 7 or day 17. 
 
PCR 
Genomic DNA was purified from day 15 embryos.  DNA samples were amplified 
using the following primers to test for V14-J TCR transgene: forward, 5’-
TGTAGGCTCAGATTCCAACC-3’ and reverse, 5’-CTCCAAAATGCAGCCTCCCTAAG-3’.  
Products were separated by agarose gel electrophoresis and visualized by ethidium 
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bromide staining.  Only embryos genotyped as positive for V14-JTCR were used 
as the source of V14 HPCs. 
 
Flow Cytometry, Antibodies, Intracellular Cytokine Staining, and Transcription 
Factor Staining 
For co-cultures, single-cell suspensions were prepared from the pooled non-
adherent cells as described above.  For in vivo experiments, single-cell suspensions were 
prepared from spleens, and hepatic mononuclear cells were separated by Percoll gradient 
centrifugation.  All cells were resuspended in staining buffer (PBS with 5% FCS).  
Antibodies to surface markers were added, and cells were stained on ice for 20 min.  
Antibodies used were from eBioscience, BD, or BioLegend. For iNKT cell staining, 
CD1d monomers loaded with biotinylated PBS57 or unloaded monomers were obtained 
from the tetramer facility of the US National Institutes of Health. Cells were analyzed on 
an LSRII (Becton Dickinson) and data was processed with FlowJo software (TreeStar).  
 For intracellular detection of transcription factors, cells were stained for surface 
markers as described above, and fixed with a Foxp3 staining buffer set (eBioscience), and 
incubated with anti-PLZF (BD Pharmigen) and anti-Tbet (eBioscience) for 30 min on ice. 
Cells were washed once before analysis on an LSRII. 
 For intracellular detection of cytokines, cells were stained for surface markers as 
described above, and then fixed and permeabilized using the Cytofix/CytoPerm buffer 
(BD Biosciences) according to the manufacturer’s protocol. Anti-IFN (eBioscience) was 
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added and the cells were stained on ice for 30 min. Cells were washed twice and then 
resuspended in staining buffer before analysis on an LSRII. 
 
In Vivo GalCer Stimulation 
For in vivo galactosylceramide (GalCer) stimulation of co-culture-derived 
cells, a single-cell suspension of non-adherent cells from the OP9-DL1 co-culture was 
prepared as described above.  These cells were washed twice with PBS before i.v. 
injection into congenically different B6.SJL (CD45.1
+
) mice.  The injected cells were 
allowed to park for 24 h before i.v. injection of 2 g of GalCer (KRN7000, Avanti Polar 
Lipids) diluted in 200 l PBS.  Three hours later liver, spleen, and thymus were 
harvested.  
 
Co-culture-derived Cell Enrichment 
Single-cell suspensions were prepared from spleens and thymi, and hepatic 
mononuclear cells were separated by Percoll gradient centrifugation.  The single-cell 
suspensions were enriched for co-culture-derived cells using anti-CD45.2 conjugated to 
magnetic beads, and MACS columns (Miltenyi Biotec), according to manufacturer’s 
protocol. 
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Statistical Analysis 
Prism software (GraphPad) was used for statistical analysis.  Unpaired or paired 
two-tailed t-tests were used for data analysis. 
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Chapter 4: Discussion 
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Conclusions 
The work presented in the second chapter of this thesis showed the Nur77
gfp
 
transgenic (Tg) mouse is a useful tool to investigate iNKT TCR stimulation during 
infection.  GFP sensitively reported stimulation by both weak and strong lipid agonists, 
as well as by both foreign- and self-lipid agonist; however, GFP upregulation does not 
distinguish TCR stimulation achieved by foreign-lipid versus TCR stimulation achieved 
by self-lipid.  Importantly, GFP was only upregulated in iNKT cells by TCR stimulation 
and not by inflammatory cytokines.  
Although the presented data indicated the indirect model of iNKT cell activation 
was not occurring during Salmonella typhimurium infection or after TLR agonist 
injection, this activation model could be occurring in other infectious contexts; for 
example, during parasitic infections, which were not examined in this thesis.  Two 
potentially interesting candidates for study are Trypanosoma cruzi (T. cruzi) and 
Schistosoma mansoni (S. mansoni).  Infections with these parasites showed iNKT cell 
activation was dependent on CD1d (163, 168).  Interestingly, iNKT cell activation during 
T. cruzi infection, although also dependent on IL-12, was independent of MyD88, an 
adaptor protein essential for the TLR activation of NFB, and therefore iNKT cell 
activation was independent of TLR stimulation (168).  During S. mansoni infection, 
iNKT cell activation in MyD88-deficient or IL-12 deficient mice was similar to WT, 
indicating that iNKT cell activation was independent of both TLR stimulation and IL-12 
(163).  Therefore, iNKT cell activation during parasitic infections may be distinct from 
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the iNKT cell activation examined during bacterial or viral infections in this thesis, and 
would be interesting to further explore using the Nur77
gfp
 Tg reporter. 
Another interesting area that was not explored in this thesis was iNKT cell 
activation during noninfectious diseases.  For example, in both allergen-induced and 
ozone-induced airway hyperreactivity, it is unknown if iNKT cell activation occurs as a 
result of TCR stimulation by endogenous lipid expressed as a result of the inflammatory 
environment, or if the inflammatory environment itself stimulates iNKT cells 
independently of antigen (95).  In cancer, in one study, iNKT cells from cancer patients 
exhibited decreased proliferation and cytokine production upon stimulation ex vivo (126).  
This anergic-like phenotype indicated that these cells were strongly stimulated (128).  
However, how iNKT cells are stimulated in cancers is not known.  Similarly to the 
models of iNKT cell activation during infection and asthma, it is hypothesized that in 
cancer, iNKT cells are activated by a stimulatory lipid from tumors (169) and/or are 
activated as a result of tumor-mediated inflammation (116).  Therefore, Nur77
gfp
 Tg 
iNKT cells could similarly help to elucidate these important questions about iNKT cell 
activation during noninfectious diseases. 
One question requiring further investigation is to what extent TCR stimulation is 
required for iNKT cell activation during infections where iNKT TCR stimulation was 
observed.  The presented data showed iNKT cell TCR stimulation is occurring during 
Streptococcus pneumoniae infection and Sphingomonas paucimobilis infection; however, 
the data does not indicate if this TCR stimulation is required for iNKT cell activation.  
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Instead, it is possible that these infections also induce cytokines by innate cells, such as 
IL-12 by dendritic cells, which are sufficient for robust iNKT cell activation in the 
absence of iNKT TCR stimulation (90).  However, this question is difficult examine 
since the iNKT TCR is required for selection, but could potentially be studied using a 
recently developed mouse model that induces TCR ablation in mature iNKT cells (156). 
Another question that remains unanswered is why the presented in vivo infection 
data from CD1d-deficient mice showed CD1d-independent iNKT activation after 
Salmonella typhimurium infection or TLR agonist injection, whereas the in vitro data 
using CD1d-deficient APCs indicated a CD1d-requirement for this activation (90).  One 
possible explanation is that the stronger stimulation of the innate immune system 
achieved in vivo may somehow inhibit TCR dependent activation of iNKT cells.  
Therefore, TCR dependent activation is only observed in the isolated culture conditions 
that occur in vitro.  Thus, it would be very interesting to test if iNKT cells from a 
Nur77
gfp
 Tg mouse will upregulate GFP after S. typhimurium infection or after 
stimulation with TLR agonists in vitro.  However, unstimulated iNKT cells unexpectedly 
exhibited elevated GFP levels in culture (data not shown), which is a problem that must 
be addressed before this question can be examined.  
Interestingly, the activation of iNKT cells during infections seems to be largely 
independent of TCR stimulation.  Additionally, even in contexts where stimulatory lipid 
is present, cytokine activation seems to be the dominate activation mechanism. Therefore, 
why do iNKT cells have a TCR?  In my opinion, the main role of the iNKT TCR is for 
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iNKT cell selection and the acquisition of the iNKT activated/memory phenotype, which 
allows iNKT cells to very rapidly secrete cytokine upon activation.   
However, recent reports indicate that the iNKT TCR may additionally be 
important for determining iNKT cell homeostasis.  In one study, the smaller iNKT cell 
population found in specific pathogen free (SPF) mice conferred protection against 
experimental iNKT cell-mediated oxazolone-induced colitis as compared to germ free 
mice (170).  This difference in iNKT cell populations between the mice indicated that 
bacterial sphingolipids may be playing a role in the establishment of iNKT cell 
populations (170).  The same group did a follow up study in which they identified 
Bacteroides fragilis as one of the bacteria responsible for this effect (162).  More 
specifically, they showed it produced a sphingolipid that affected the expansion of the 
iNKT cell population during development in germ free mice (162).  Interestingly, the 
function of this lipid is inhibitory instead of stimulatory.  However, the mechanism of 
inhibition is unclear; therefore, it would be interesting to look at this phenomenon in 
Nur77
gfp
 Tg mice to investigate if stimulation of the iNKT TCR is involved similarly to 
activating lipids.  
The work in the third chapter of this thesis presented a new culture system using 
V14 Tg hematopoietic progenitor cells to derive iNKT cells in vitro.  Importantly, this 
new culture system induced a robust and stable population of CD1d/GalCer tet+ cells, 
which will allow for further examination of factors that influence iNKT cell 
development.  Additionally, this culture system can be used to investigate what factors 
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are needed to skew iNKT cell subset development to derive the subset most beneficial for 
individual disease treatment. 
For example, IFN production has been shown to essential for the antitumor 
response (61).  Therefore, NKT1 cells, which produce IFN, would be the subset most 
beneficial for therapeutic use (57).  In this work, I tested whether IL-15 could skew the 
cultured cells to develop into the NKT1 subset.  Interestingly, the addition of IL-15 
resulted in an increase in the percentage of CD1d/GalCer tet+ cells expressing Tbet.  
However, it is unclear whether this increase was due to increased cell survival, or if IL-15 
caused more cells to express Tbet.  However, because Tbet promotes the upregulation of 
CD122 (the IL-15 receptor  chain) (61), it seems more likely that the addition of IL-15 
is having a survival effect on these cultured cells.  Therefore, the factors involved in the 
initiating Tbet expression and NKT1 subset differentiation remain to be identified.  Yet 
another group of lymphocytes, which like iNKT cells, have characteristics similar to 
innate immune cells, also have subsets similar to the iNKT cell subsets (171).  Therefore, 
factors involved in the differentiation of these cells, which are called innate lymphoid 
cells (ILCs), are also potential candidates for involvement in iNKT cell subset 
differentiation.  The ILC subset most similar to NKT1 cells are cytotoxic ILCs. 
Therefore, based upon cytoxic ILC development, factors that could skew iNKT cell 
development toward NKT1 cells are IL-12 and/or IL-18 (171).  These cytokines could 
also be tested in combination with IL-15 (171).  
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In contrast, the therapeutic use of NKT1 cells for treatment of type I diabetes 
would be harmful.  Previous studies about the role of iNKT cells in type I diabetes 
indicate that aid provided by iNKT cells stems from their ability to shift the TH1 
cytokine bias toward a TH2 cytokine bias (94, 114).  Therefore, NKT2 cells would be the 
most beneficial subset for type I diabetes treatment.  However, the factors that initiate the 
development of NKT2 also remain to be identified.  The ILC that most resembles the 
NKT2 are Type 2 ILCs (ILC2).  Based upon ILC2 development factors, IL-25 and/or IL-
33 are potential candidates for skewing iNKT cell development toward NKT2 cells (171). 
Although a therapeutic use for the NKT17 subset is unclear, determining the 
factors involved in the development of this subset is still important for the general 
understanding how this subset can influence an immune response.  For example, IL-17 
produced by NKT17 cells is required for the development of some asthma models (106).  
Therefore, insight into the development of this subset may provide insight into the 
pathogenesis of IL-17 dependent asthma.  Again, the factors that are involved in NKT17 
development remain to be identified.  However, the ILC most similar to NKT17 cells are 
Rort+ ILCs.  The factors that influence the development of these ILCs are IL-1 and IL-
23 (171).  Therefore either or both of these cytokines are potential candidates for skewing 
iNKT cell development toward the NKT17 subset. 
 In conclusion, the work done in this thesis identified the Nur77
gfp
 Tg mouse as a 
reporter specific for TCR stimulation in iNKT cells.  Here, antigen-independent 
activation was identified as the main mechanism for iNKT cell activation during 
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Salmonella typhimurium infection, and injection of TLR agonists implicated that TLR-
stimulating infections are also activating iNKT cells in an antigen-independent manner.  
Furthermore, this work indicated that the Nur77
gfp
 Tg mouse can be used to explore the 
role of the antigen stimulation in additional infections, as well as in disease models where 
the role of antigen stimulation in iNKT cell activation is unclear.  This additional insight 
into when the different models of iNKT cells activation occur may provide new ways to 
control iNKT cells during a variety of diseases.  This work also identified a new culture 
system for the in vitro derivation of an exogenous source of iNKT cells.  It provided a 
new platform for examining the conditions that influence iNKT cell development and for 
determining the specific factors that can skew iNKT subset development.  The ability to 
derive a specific iNKT cell subset is essential for iNKT cell therapies, as different iNKT 
cells subset will have different effects on the same disease.  Therefore, this work has 
identified new tools for further understanding of how iNKT cells develop and are 
activated, which is crucial for harnessing the immunomodulatory potential of iNKT cells 
for use in iNKT cell based therapeutics. 
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